Mangos and their bioactive components: Adding variety to the fruit plate of health.

Britt M. Burton-Freeman* 1, 2, Amandeep K. Sandhu1, Indika Edirisinghe1

1
Center for Nutrition Research, Institute for Food Safety and Health, Illinois Institute of
Technology, IL, USA

2
Department of Nutrition, University of California, Davis, CA, USA

RUNNING TITLE: Mangos, Bioactive components and Health

*To whom correspondence should be addressed:

Britt M. Burton-Freeman, PhD, MS
Center for Nutrition Research, Institute for Food Safety and Health, Illinois Institute of
Technology, Room 339/338, Bldg. 91, Moffett Campus, 6502 South Archer Rd., Bedford Park,
IL 60501-1957
Email: bburton@iit.edu
Fax: 708-341-7078

1
Abstract

Diet is an essential factor affecting the risk for the development and progression of

modern day chronic diseases, particularly those with pathophysiological roots in inflammation

and oxidative stress-induced damage. The potential impact of certain foods and their bioactive

compounds to reverse or prevent destructive dysregulated processes leading to disease has

attracted intense research attention. The mango (Mangifera indica Linn.) is a tropical fruit with

distinctive nutritional and phytochemical composition. Notably, the mango contains several

essential water- and lipid- soluble micronutrients along with the distinguishing phytochemicals

gallotannins and mangiferin. In vitro and in vivo studies reveal various mechanisms through

which mangos or their associated compounds reduce risk or reverse metabolic- and

inflammation- associated diseases. Health benefits of isolated individual mango compounds and

extracts from mango by-products are well described in the literature with less attention on the

whole fruit. Here, we review and summarize the available literature assessing the health

promoting potential of mango flesh, the edible portion contributing to the fruit plate of the diet,

focusing specifically on modern day health issues of obesity and the risk factors and diseases it

precipitates, including diabetes and cardiovascular disease. Additionally, the review explores

new insights on the benefits of mango in brain, skin and intestinal health. Overall, the foundation

of research is growing and supporting the potential role for mangos in reducing risk for

inflammation- and metabolically- based chronic diseases.

KEY WORDS: mangiferin, gallotannin, polyphenols, gallic acid, diabetes, cardiovascular

disease, inflammation, oxidative stress, insulin resistance, obesity

2
Introduction

Consuming a diet rich in fruits and vegetables is associated with a number of health

benefits, including maintaining physiological function and reducing risk of a number of age and

lifestyle related diseases, including cardiovascular disease (CVD), type 2 diabetes mellitus

(T2DM), Alzheimer’s disease, cancers, among others 1. In addition to contributing essential

vitamins and minerals, fruits and vegetables also provide health promoting phytochemical

components. The role of these components in health and disease risk reduction has been the

subject of intense study in recent years. Risk factor reduction may occur through the action of

these components’ ability to impact cellular processes to maintain “normal” tissue function and

or their ability to reestablish normal homeostasis when pathological shifts are underway. Recent

hypotheses have focused on characterizing various health promoting attributes of fruits,

including defining their phytochemical content and composition, their bioavailability and

metabolite profiles, and determining their effects on health/disease risk endpoints. The focus of

the present paper is on mango fruit and their bioactive components relative to health promoting

properties.

Prior reviews on the health benefits of mango have focused on the bark, leaves, peel, and

seed/kernel due to their high content of pharmacologically-active compounds and health

promoting effects. In contrast, very little information is available on the flesh/pulp, the part

which is mainly consumed as fresh produce or processed for juice or ingredients, such as purees

and dried fruits. Mangos represent a fruit with distinctive nutritional and phytochemical interests

for researchers, consumers and health professionals. Research is unveiling new insights about

mangos and their role in adding variety to the fruit plate of health. The present review discusses

these findings providing a brief background about the mango followed by a review of the

3
nutritional and phytochemical composition of mango fruit flesh/pulp, bioavailability of major

compounds and current knowledge associated with body weight control, diabetes development

and management, and related metabolic disturbances. Additionally, the paper will briefly explore

new areas of opportunity for mango pulp delivering benefits for brain, skin and intestinal health.

Information on mango peel, kernels, bark, and leaves or individual compounds are the topic of

many other reviews, including many that have focused on cancer 2-5 and will not be discussed in

any length here, although reference to fruit by-products or individual compounds are included for

context, as appropriate. Research was identified primarily in Medline with PubMed searches on

the following keywords: “mango”, “mangos”, “mango pulp”, “mango flesh”, “polyphenols”,

“mangiferin”, “gallic acid”, “gallotannin”, “carotenoids” in association with “cardiovascular

disease”, “heart disease”, “diabetes”, “inflammation”, “intestine”, “oxidative stress”,

“oxidation”, “body weight”, “obesity”, “Alzheimer’s disease”, “skin”, “metabolism”,

“pharmacokinetics”, “bioaccessibility” and “bioavailability”. Searches were also conducted in

Web of Science and by cross-reference reviewing of published papers.

Mango background

Mango (Mangifera indica Linn.) is a commercially important tropical fruit in the family

Anacardiaceae. Mangos are stone fruits (drupe) containing one large seed surrounded by yellow-

orange flesh. They have a rich cultivation history starting thousands of years ago in Southeast

Asia. Today, mangos rank 4th in total production among major fruit crops worldwide

contributing over 45,000,000 tons per year to the global fruit market 6. Mango producing

countries are manly tropical and sub-tropical, including India, China, Thailand, Indonesia,

Philippines, Pakistan, and Mexico. However, since the 1970’s mango production has increased

4
dramatically owing to increased production in non-traditional growing regions such as southeast

United States of America (USA), Central and South America, Australia, Hawaii among other

locations.

There are several hundred cultivars of mango; however, the world market is currently

dominated by the cultivar “Tommy Atkins” due to its long shelf life and excellent ratings in

handling and transport tolerance. In addition to Tommy Atkins, consumers in the USA may also

find Ataulfos, Francis, Haden, Keitt, Kent, and Palmer cultivars 7. Each mango cultivar varies in

size, shape, color, texture and flavor. The pulp (edible part) of mango constitutes around 40-65%

of total fruit weight depending upon variety 3 while the remaining portion is peel and seed, which

is discarded as waste. Mangos are a climacteric fruit, which means they will ripen off the tree.

The period of ripening is characterized by a series of endogenous biochemical changes, including

enhanced production of ethylene and increased respiration rate 8. With ripening, mango cultivars

achieve their characteristic color, taste, aroma and desired softening. During this period

nutritional and phytochemical composition will also change. Mangos are one of the few fruits

that are utilized at different stages of growth and maturation. For example, “green” fruit may be

used for products like pickles, chutney or sauces or beverages (panna), whereas ripe fruits may

be eaten as fresh products, sliced for frozen or canned applications or made into fruit leathers,

purees, nectar, or juices among other processed products. Besides commercial processing, their

use is increasing in culinary applications such as in the preparation of salsas, fruit salads,

chutneys, ice-creams and other mango flavored desserts 8.

Nutritional and Phytochemical Content of Mangos

5
 Mangos contain various nutrients including carbohydrates, organic acids, dietary fiber,

and vitamins C along with other vitamins and minerals (Table 1). The major soluble sugars in

mango are sucrose, fructose and glucose, while citric and malic acid are the predominant organic

acids 9. The fruit taste is dependent upon the balance between these two components and their

content varies from 40-77% depending upon stage of maturity 10. Apart from the essential

nutrients, mangos contain considerable amounts of non-essential components known as

phytochemicals. Mangos consist of both simple and complex phytochemicals, most notably

phenolic acids, mangiferin, carotenoids and gallotannins 11.

Phenolic acids: Mango flesh contains both hydroxybenzoic and hydroxycinnamic acid

derivatives, the two major categories of phenolic acids in plants. These phenolic acids are present

in free or conjugated forms, commonly as simple esters with quinic acid or glucose 12, 13. Among

the hydroxybenzoic acids, gallic acid, vanillic, syringic, protocatechuic acid, p-hydroxybenzoic

acid have been reported in flesh while hydroxycinnamic acid derivatives include p-coumaric

acid, chlorogenic acid, ferulic acid and caffeic acid 14, 15. The phenolic acid type and content

varies with variety, geographical location and ripening stage. Abbasi et al., 2015 14 compared the

phenolic acid content in the pulp and peel of nine mango cultivars grown in China. Ferulic acid

was reported to be highest in mango pulp measuring up to 33.75±1.44 mg/100 g fresh weight

((FW)), followed by protocatechuic (0.77±0.01- 6.83±0.53 mg/100 g FW), chlorogenic

(0.96±0.06- 6.20±0.41 mg/100 g FW), gallic (0.93±0.08- 2.98±0.23 mg/100 g FW), vanillic

(0.57±0.09- 1.63±0.09 mg/100 g FW) and caffeic acids (0.25±0.04- 1.12±0.10 mg/100 g FW).

Similarly, the major phenolic acids in Ataulfo mango pulp were identified and quantified at four

ripening stages 15. Chlorogenic acid was most abundant in Ataulfo mango pulp, followed by

6
gallic, vanillic and protocatechuic acids showing an increase of 90%, 4%, 30% and 56% at the

final ripening stage, respectively.

Contrary to these studies, Kim et al., 2009 16 reported gallic acid as the major phenolic

acid in mango pulp (Tommy Atkins cultivar) since they were unable to quantify the other

identified phenolic acids (p-hydroxy benzoic, p-coumaric, and ferulic acids) due to low

concentration. Compared to other fruits like banana, guava and orange, mango showed the

highest content of total (soluble and insoluble fraction) phenolic acids, with gallic acid reported

in the highest content 17. Likewise, in another study comparing phenolic acid content of mango,

durian and avocado fruits, mangos had the highest content of gallic acid and total phenolic acids
18
.

Carotenoids: Carotenoids are lipid soluble pigments responsible for yellow, orange and red color

of the skin and flesh of mangos, although the reddish color of skin in some cultivars is

contributed by anthocyanins as well 11. Mangos contain two classes of carotenoids i. e.,

hydrocarbon carotenoids (such as α-carotene, β –carotene and γ-carotene), and oxygenated

derivatives known as xanthophyll’s (such as auraxanthin, antheraxanthin, neoxanthin, lutein,

violaxanthin and zeaxanthin) 19, 20. Apart from compositional variation among different mango

cultivars due to factors such as genetic, environmental, stage of maturity, production practices,

postharvest handling, processing, and storage 21, the major discrepancies in qualitative and

quantitative data reported by different authors could be due to analytical procedures employed

and the unstable nature of carotenoids. More than 25 different carotenoids (free form, butyrates

and esterified compounds) have been identified 22, 23, however, the most abundant carotenoids in

mango flesh appear to be all-trans-β-carotene, and all-trans- and 9-cis-violaxanthin 22, 24, 25. A

7
study on seven Mexican mango cultivars reported the highest content of carotenoids was

contributed by all-trans-β-carotene (ranging from 0.4-2.8 mg/100 g FW), all-trans-violaxanthin

(0.5-2.8 mg/100 g FW) and 9-cis-violaxanthin (0.4-2.0 mg/100 g FW). Among different

cultivars, Haden mangos had the highest content of all the three carotenoids 22. Mango cultivar

Keitt from Brazil showed the highest content of all-trans-violaxanthin (2.1±0.3 mg/100 g FW),

followed by all-trans-β-carotene (1.5±0.2 mg/100 g FW), and 9-cis-violaxanthin (1.0±0.0

mg/100 g FW) 24. β-carotene content in five different mango cultivars (Tommy Atkins, Haden,

Keitt, Kent, and Ataulfo) obtained from four countries with multiple harvests over a year varied

between 5-30 mg/kg FW puree (ie., 0.5-3.0 mg/100 g FW puree). The results showed that fruit

cultivar had a greater influence on the β-carotene content than the country of origin or harvest

date 26. Another study compared the total carotenoid levels in 12 mango cultivars from

Bangladesh at various stages of maturity (green, semi-ripe and ripe stages). The carotenoid

content increased from green (0.003 mg/100 g edible portion) to semi-ripe (0.07 mg/100 g edible

portion) and ripe stage (0.25 mg/100 g edible portion) 27.

Xanthones/Xanthonoids: These are bioactive compounds with C6-C3-C6 backbone structure

with hydroxyl, methoxyl and isoprene units attached on A and B rings resulting in wide array of

compounds, but mostly occur as ethers or glycosides 28. They are found in a few higher plant

families, fungi and lichen 29. Six xanthone derivatives have been identified in Mango pulp

namely mangiferin, dimethylmangiferin, homomangiferin, mangiferin gallate, isomangiferin and

isomangiferin gallate 30-32. The content of mangiferin and derivatives is very low in pulp

compared to peel and seed. Mangiferin content in the pulp of Pica and Tommy Atkin cultivars

from Chile was reported to be 4.24±0.10 mg/100 g FW and 3.25±0.10 mg/100 g FW,

respectively 31. Out of 11 Chinese mango cultivars studied, mangiferin was only detected in the
8
pulp of 5 cultivars with values ranging from 0.002-0.20 mg/g dry matter (0.032-3.20 mg/100 g

FW, values converted to fresh weight assuming 84 % moisture content in mangos) 30. Among

four Brazilian mango cultivars the mangiferin content was highest in Uba cultivar 12.4±0.3

mg/kg dry matter (0.2±0.0 mg/100 g FW, values converted to fresh weight assuming 84 %

moisture content in mangos) and was not detectable in the pulp of Palmer cultivar 32. Harvest

date and geographical location can also impact the mangiferin content. Ataulfo mango showed

increases in mangiferin content depending on harvest dates of early and late ranging from 22.7-

99.6 mg/100 g puree. Kent cultivar from Peru showed the highest mangiferin content at

11.0±11.6 mg/100 g puree while it was present only in trace amounts in Kent cultivar from

Ecuador 26. Two studies reported significant variation among cultivars in the content of

mangiferin derivatives in the pulp. For example, Ramirez et al., 2013 31 quantified mangiferin

gallate in the pulp of Pica cultivar at 2.35±0.03 mg/100 g FW; however, it was not detected in

the pulp of Tommy Atkins cultivar. Similarly, mangiferin gallate was not detectable in 3

Brazilian mango cultivars and only a small amount was present in Uba cultivar (1.3±0.00 mg/kg

dry matter, 0.02±0.00 mg/100 g FW, values converted to fresh weight assuming 84 % moisture

content in mangos) 32. The content of homomangiferin varied between 1.71-1.96 mg/100 g FW

in Tommy Atkins and Pica mango pulp. A small amount of dimethylmangiferin was also

detected in the pulp of Pica mango cultivar 31. In some Brazilian mango cultivars, isomangiferin

ranged from not detected to 1.1 mg/kg dry matter (or on FW basis: not detected to 0.02 mg/100 g

FW) and isomangiferin gallate was only present in Uba cultivar (4.5 mg/kg dry matter or 0.07

mg/100g FW) 32.

Flavonols: Flavonols are flavonoid compounds and consists of the characteristic C6-C3-C6

backbone structure and double bonds between C-2 and C-3 of the C ring. They are commonly
9
present as O-glycosides but methylated, malonated and acetylated derivatives have also been

reported 33-35. The predominant flavonols in mango pulp are quercetin glycosides (glucose,

galactose, rhamnose, xylose and arabinose) with kaempferol, isorhamnetin, fisetin and myricetin

also reported in small quantities 18, 31, 36, 37. Quercetin-3-O-glucoside is the major flavonol in

mango pulp with values varying from 1.70±0.04 mg/100 g FW to 2.66±0.08 mg/100 g in Pica

and Tommy Atkins cultivars, respectively31.

Flavan-3-ols and condensed tannins: Flavan-3-ols and condensed tannins are monomeric and

oligomeric compounds, respectively. They are flavonoid compounds formed from the

characteristic C6-C3-C6 backbone structure, but without oxygenation at C4 and lack double

bonds between C2-C3 of the C ring. Catechin and epicatechin are the monomeric units of

condensed tannins, also known as proanthocyanidins 38. Mango pulp contain monomeric units

and catechin appears to be most abundant (1.72±1.57 mg/100 g FW) 39 and epicatechin is present

in very low amounts, approximately 0.15±0.0 mg/100 g FW 40. Ramirez et al., 2014 31 identified

procyanidin A dimers and its galloylated form in mango pulp. A comprehensive study on the

proanthocyanidin content of some common foods reported that mango pulp contains monomers

(2.3±0.1 mg/100 g FW), dimers (1.8±0.0 mg/100 g FW), trimers (1.4±0.0 mg/100 g FW) and

tetra-hexamers (7.2±0.5 mg/100 g FW) 41.

Gallotannins and derivatives: Gallotannins are classified as hydrolysable tannins and consist of

galloyl groups completely or partially substituting the hydroxyl groups of glucose (as a core

molecule) resulting in a wide array of gallotannin derivatives. However, other polyols such as

glucitol, hammamelose, shikimic acid, quinic acid and quercitol have also been reported as core

molecules in some species 42. In mango pulp, 11 gallotannins and their isomers have been

10
identified in different cultivars, including mono, di, tri, tetra, penta, hexa and hepta galloyl
43-45
glycosides . Apart from the aforementioned, several other gallic acid derivatives including

conjugated forms with methyl groups have also been reported 45.

Recognizing that mangos are a climacteric fruit, they are generally harvested while still

green and stored until ready for distribution. It is not possible to harvest all mangos at the same

maturity stage which could be one of the factors affecting the homogeneity of batches, thus

affecting the overall quality and nutrient composition 46. In addition, the variability in

phytochemical composition of mangos could be affected by several pre- and post-harvest factors

such as environmental conditions (light, temperature, carbon and water availabilities), genetic

factors, cultural practices, maturity at harvest, postharvest handling, storage and processing 46, 47.

Therefore, a certain amount of variability in values might always be expected making it

important that fruit interventions in health research are chemically characterized. This chemical

characterization, including content of components aid in reproducing findings across labs and

contribute to the science-base for making dietary recommendations. Likewise, when expected

biological effects are not observed, knowing the chemistry of fruit may be critically insightful in

explaining results.

Bioavailability and metabolism of mango phytochemicals

Bioactive components (phytochemicals) from different dietary sources require being bio-

accessible and to some degree bioavailable, depending on target organ system, to exert beneficial

health effects. Bioaccessibility and bioavailability are two different terms used in

pharmacokinetic analysis. For example, bioaccessibility is defined as the release of bioactive

components from food matrix for absorption in the gastrointestinal tract (GI) 48 while

11
bioavailability is defined as the fraction of ingested compound or its metabolite that reaches the

systemic circulation to exert a biological effect 49. Bioavailability has a much broader meaning

and includes digestion, absorption, metabolism, distribution and elimination of bioactive

components/metabolites from the body. Phytochemical metabolism involves partial or complete

degradation of compounds, changes in the functional groups (e.g., methylation, sulphation, etc.)

and or conjugation with other molecules (e.g., glucuronidation, plasma proteins).

Mangos contain fat soluble (carotenoids) and water soluble (polyphenols)

phytochemicals, both having different pathways of absorption and metabolism. In general,

polyphenols are absorbed in the body in their aglycone form with the exception of some

compounds such as anthocyanins. Their metabolism occurs throughout the GI tract beginning in

the mouth by action of salivary enzymes and resident microflora where only limited hydrolysis

of glycosides takes place. The structural modification of polyphenols (deglycosylation,

hydrolysis) occurs in the stomach and small intestine (pH effects) along with the action of

resident enzymes. Compounds that escape absorption from the upper GI tract pass to the large

intestine where they undergo extensive breakdown by endogenous and microbial enzymes to

phenolic acids and various other small molecules. The absorbed compounds can be further

metabolized (glucuronidated, methylated and sulphated) by phase I and II enzymes in the small

intestine, liver, kidney and various body tissues. While most of the absorbed

compounds/metabolites will enter general circulation, some compounds will be excreted back

into the small intestine via bile and be re-absorbed via entero-hepatic circulation. The kidney is

the primary clearance pathway for absorbed compounds via excretion in urine. Unabsorbed

phenolic compounds and microbial metabolites are excreted in feces.

12
 Carotenoids, which are fat soluble phytochemicals undergo a different metabolic pathway

than water soluble polyphenols. They are released from the food matrix by mastication, gastric

action and digestive enzymes 50. After being incorporated into micelles formed by dietary fat and

bile acids, carotenoids are absorbed in the intestinal lumen (enterocytes) by passive diffusion and

active uptake by apical membrane transporters 51. Carotenoids like β-carotene are cleaved by

enzymes within the enterocytes producing Vitamin A, and corresponding esters and oxidized

forms which are incorporated into triglyceride rich lipoproteins called chylomicrons. The

chylomicrons are metabolized forming chylomicron remnants. Chylomicrons and their remnants

deliver carotenoids to extrahepatic tissue, but most will return to the liver where they are stored

or re-secreted into blood with the very low density lipoproteins 50.

The bioaccessibility and bioavailability of mango phytochemicals has been studied in

vitro and in animal models. Most of the bioavailability studies used isolated compounds

(mangiferin) or extracts from mango leaf and mango seed kernels, which does not represent the

delivery/absorption of phytochemicals from a complex food matrix such as mango pulp.

However, there are a few in vitro, animal, and human studies assessing the bioavailability of

phytochemicals from mango pulp (Table 2). In an in vitro digestion and absorption model,

Epriliati et al., 2009 52 found that dried mango and fresh fruit released lower levels of nutriome

components (sugars, organic acids and β-carotene) than juices. The same group conducted

another study using Caco-2 cell monolayers as human intestinal absorption model to investigate

nutriome passages (sugars, organic acids and phytochemicals) from fruit digest solutions of

fresh, dried and juiced mango, and concluded that phytochemical constituents, including

carotenoids were not absorbed from the small intestine based on this model 53. They also

predicted that pectin might play a role in determining the rate of nutriome release and absorption.
13
In a simulated in vitro digestion model, the micellarization of β-carotene from Ataulfo mango

pulp at different ripening stages in the absence or presence of chicken baby food was evaluated

and uptake by Caco 2 cells was studied 54. The micellarization of β-carotene from mango pulp

increased with fruit ripening and in the presence of chicken baby food. However, the uptake of

micellarized β-carotene by Caco 2 cells was only 17%. Low and co-workers conducted a series

of studies on the effects of mastication on bioaccesibility of mango pulp phytochemicals

followed by in vitro digestion and fermentation to mimic the effects of the GI tract 55, 56.

Mastication influences particle size and surface area of food. After in vitro digestion, smaller

particles showed a greater % release of carotenoids, however bioaccessibility of xanthophylls

was higher than β-carotene irrespective of particle size 55 . In vitro fermentation of chewed

mango resulted in the formation of catabolites such as 4-hydroxyphenylacetic acid (within 4-8

h), while other compounds such as catechin derivative and 3-(4-hydroxyphenyl) propanoic acid

were apparent at 48 h 56. Blancas-Benitez et al., 2015 57 studied the bioaccessibility of

polyphenols associated with dietary fiber and the kinetics of release of polyphenols in mango

(Ataulfo) paste and peel. The results showed that polyphenols associated with soluble fiber were

higher than insoluble fiber in mango paste and the bioaccessibility of polyphenols from mango

paste was around 39%. Gallic acid and hydroxybenzoic acids were the major polyphenols

released after digestion reaching maximum concentration at 180 min. In a recent study aimed to

increase the bioaccessibility of phenolics and carotenoids from mangos, oil-in-water excipient

nanoemulsions were prepared, mixed with pureed mango and passed through a simulated GI

tract. An increase in lipophilic bioactives was observed in nanoemulsions made with long chain

triglycerides vs medium chain triglycerides; however, bioaccessibility of phenolics remained

unaltered 58 (Table 2). There is only one animal model study conducted to study the effect of

14
food matrix (mango and carrots) on bioconversion efficiency of β carotene to Vitamin A 54, 59. In

this study, Vitamin A depleted rats were fed with the same daily dose of β carotene from Ataulfo

mango, carrots and synthetic β carotene with and without soy bean oil. The results showed that

rats fed with carrots accumulated 37% less retinol than those fed mango without oil. A human

clinical trial assessing the bioavailability of carotenoids from mango (fresh, juice and dried)

showed an increase in plasma carotenoid content after all mango treatments, but was highest

after volunteers consumed the fresh mango followed by juice and then dried mango 60. The most

recent clinical study was published by Barnes and co-workers 61 in which they evaluated the

urinary excretion of galloyl metabolites after 10 day consumption of mango fruit. They

characterized and quantified seven galloyl metabolites in urine; however, nothing was detected

in plasma. This could be due to limited bioavailability of polyphenols from mango pulp which

could be affected by several factors including food matrix, dose, inter-individual variations,

study design, or interactions of polyphenols and other food components during digestion and

absorption. Instrumentation sensitivity and analytical challenges could also result in undetectable

polyphenols and their metabolites.

Overall, the phytochemicals of mango are accessible for absorption; however, the site and

mechanism of absorption differs depending on the characteristics of the phytochemical and to

some degree the composition of co-ingested nutrients (i.e., lipids enhance carotenoid absorption).

Much less is known about the bioavailability and pharmacokinetic characteristics of polyphenol

constituents of mango fruit, yet the field is advancing to help understand the relationship

between these component and their health benefits.

Obesity and Diabetes: Pathophysiology and Diet, general

15
 The prevalence of obesity and type 2 diabetes has increased sharply around the world

over the last two decades. The growth in both has presented health care challenges aimed toward

managing complications and reducing incidences. Obesity is characterized by excess adiposity,

although it is defined more routinely by a body mass index (BMI) of ≥ 30 kg/m2. In Asia, obesity

may be defined at a lower BMI based on associated health risks 62. Obesity is a major risk factor

for type 2 diabetes and a number of other diseases, including cardiovascular diseases (CVD),

osteoarthritis, non-alcoholic liver disease and some cancers. Obesity is typically characterized by

a state of chronic low grade inflammation, oxidative stress, hyperglycemia, hyperlipidemia and

insulin resistance, which serves to promote a number tissue and organ disturbances and

complications, from diabetes and CVD to Alzheimer’s disease and cancer. Even in the absence

of obesity modern day eating patterns comprised of excess calories, readily available

carbohydrates and fats induce acute increases in glycemia, insulinemia, lipemia and markers of

inflammation and oxidative stress. Considering that people eat multiple times a day, every meal

becomes an opportunity for metabolic and inflammatory stress; or alternatively, an opportunity

for maintaining balance and protecting cells from the discourse of metabolic-oxidative-immuno-

disruption 63. Therefore, the diet is a critical preventive and therapeutic tool to combat the

processes underlying obesity and diabetes and the aforementioned non-communicable diseases

apparent today.

Among the most consistent advice for promoting health and reducing disease risk is

regular consumption of fruits and vegetables. Unlike vegetables, the recommendations for fruit

intake are general and there is interest in the role individual fruit types can play in health,

particularly tropical fruits.

16
Mangos and Obesity and Diabetes

Mangos are a source of phytochemicals with a number of health attributes assigned to

them, including anti-inflammatory, antioxidant, anti-diabetic, anti-obesity, anti-cancer, among

others. The literature is dense in studies examining these effects using extracts from mango

leaves, seeds, peels, bark and individual compounds such as mangiferin; however, very little of

this work has been conducted after consuming the mango fruit. Reviewing the literature, we

found only four articles studying obesity and or diabetes outcomes in animal models 64-67 (Table

3) and seven reports in humans 68-74 (Table 4). Much of the in vivo work on inflammation was

captured as secondary measures in the aforementioned investigations or in models of colitis 75, 76.

In vivo evaluation of antioxidant properties of the mango flesh are few, captured in studies

discussed in this paper or in animal models studying cancer 77, 78. Much of the antioxidant work

is conducted in cell culture and with extracts of individual compounds: mangiferin, gallotannins,

gallic acid and are difficult to translate into in vivo effects 11, 79, 80. The concentration at which

compounds are used for in vitro studies may not relate to their concentration in vivo.

Apart from the few investigations available for review, important findings have been

revealed about mangos relative to obesity and diabetes. The in vivo animal data using the high fat

fed diet-induced obesity model suggests that mango and its associated constituents may have a

role in reducing risk for obesity and diabetes. In this model, high fat diets increase weight gain

and fat accumulation that leads to metabolic- oxidative- and immune- disruption that manifests

in pre-disease states similar to those observed in humans, such as pre-diabetes and metabolic

syndrome characterized by insulin resistance, glucose intolerance, dyslipidemia, elevated

markers of inflammation, endothelial dysfunction, among others. Studies in rodents

17
supplemented with mango juice or freeze-dried mango fruit (1-10% of diet) reduced the high fat

diet-induced increases in weight gain 64, increases in fat mass 64, 65 and impairments in metabolic

endpoints, including reducing insulin resistance, total cholesterol (TC), TC to high density

cholesterol (HDL) ratio, triglycerides (TG) and glucose concentrations 64, 65. The data from these

studies suggest that the action(s) of mango constituents may be due to changes in inflammatory

status and adipose morphology possibly due to changes in fatty acid metabolism (i.e.,

peroxisome proliferator-activated receptor gamma (PPAR-γ), lipoprotein lipase (LPL) and fatty

acid synthase (FAS) expression 64. Another study using the same high fat diet-induced obesity

model in mice found a dose of 10% mango in the diet (w/w) increased body weight and fat

accumulation in mice compared to high fat diet alone or the 1% mango supplemented mouse

diet, however, the 10% mango diet was the most effective in modulating gut bacteria in favor of

Bifidobacteria and Akkermansia 66, bacteria that have been associated with reduced obesity and

improved metabolic outcomes 81. The study also found increased short chain fatty acid

production and modulation of gut inflammatory cytokines, of which mango (at 1% or 10% of the

diet) significantly increased the expression of anti-inflammatory cytokine interleukin 10.

In addition to diet-induced obesity, alloxan treatment induces type 1 and type 2 diabetes.

Alloxan is toxic to the insulin secreting beta cells of the pancreas diminishing or fully ablating

beta cell function. In an alloxan-induced diabetes model, mango pulp flour made from the

Tommy Atkins cultivar was tested for effects on weight gain, energy intake, glycemia and

hepatic glycogen content in a 30 day and 90 day protocol 67. The 90 day protocol was designed

to further test the lowest effective dose (5% mango flour) determined in the 30 day trial. Blood

glucose concentrations at the end of 90 days was 66% lower than that in the diabetic controls and

hepatic glycogen levels of the animals fed mango flour was 64% greater than in the controls. In
18
addition, the animals fed mango had a higher serum insulin level (p < 0.05) than those in the

control group, which indicated restoration of beta cell function damaged by the alloxan

treatment. Results also suggested animals were healthier and more metabolically stable on the

mango diet as suggested by increased food intake and body weight gain, since the processes of

uncontrolled diabetes induce accelerated catabolism of proteins, carbohydrates and fats and

weight loss. The effects of the mango treatment on hepatic glycogen content are important and

indicate restoration of glycogen metabolism shown to be diminished in poorly controlled type 1

and type 2 diabetes 82, 83. Stimulation of net hepatic glycogen synthesis is relevant in glycemic

control in general, and may be another mechanism by which mangos exert their anti-diabetes

effects. Small amounts of fructose can have a catalytic effect in stimulating hepatic glycogen

synthesis in humans augmenting hepatic glucose uptake and lowering the glycemic response to

dietary carbohydrate. This may explain why lower doses of mango (1% of diet) performed better

than higher doses in glucose tolerance test 65.

In humans, seven trials were identified that fed mango fruit or puree to individuals and

measured obesity or diabetes endpoints. Among these, five were conducted in individuals

diagnosed with type 2 diabetes and two were in people without diabetes who were obese 71 or

generally healthy 70. Among the non-disease groups, mango supplementation (10 g freeze-dried

powder/d, Tommy Atkins) reduced glucose concentrations after 12 weeks compared to baseline

measures (no control arm studied). The glucose-lowering effect of mango was observed in both

male [-4.5 mg/dL (-0.25 mmol/L), P = 0.018] and female [-3.6 mg/dL (-0.20 mmol/L), P =

0.003] participants and was not associated with changes in body weight or body composition,

although men were reported to have reduced waist circumference 71. In a three-arm randomized

controlled crossover design in healthy Mexican adults (n=38, 19 male, 19 female) fresh mango
19
puree (Tommy Atkins) resulted in a lower glucose response over 2 h compared to an equivalent

amount of glucose (control); and purees that were hydrostatic high pressure processed resulted in

lower glycemia than unprocessed puree, suggesting an opportunity for the food industry to

consider technologies in their product development strategies that can deliver enhanced health

promoting foods for people concerned about glucose control.

Studies conducted in people diagnosed with type 2 diabetes assessed the effects of mango

on glycemic endpoints compared to glucose control 69, white/wheat bread controls 72, 73 and or

other fruits 68, 69, 72-74. Available carbohydrate was matched at either 50 g or 25 g equivalents and

testing was performed over 2 or 3 h (Table 4). In three of the five studies in people with

diabetes, mango reduced acute glucose excursions compared to 50 g glucose control 69 and 25 g

carbohydrate equivalent wheat bread or alternative fruit control 73, 74. Two other studies in people

with diabetes reported either no difference in glycemia between mango and banana 68, 74 or

increased glucose compared to white bread control 72. The reason for the discrepancy in findings

may be related to the diversity of the population being studied, since people can be at different

stages of disease and be using different forms of medication for disease management.

Additionally, sample sizes were relatively small (n=10-13) for the between subject variance

expected in these trials. Two studies also measured postprandial insulin with no difference

between mango and white bread control treatments 72 or other tropical fruits 74, except when

compared to durian fruit, where the area under the insulin concentration curve was lower after

mango compared to 25 g carbohydrate equivalent of durian fruit 74. Collectively, the research

suggests that people with diabetes mellitus do not experience heightened glycemic responses

when consuming mango fruit; and moreover, there may be indication for therapeutic benefits

specific to certain fractions of mango, including fractions rich in gallotannins and mangiferin 84,
20
85
. Less well understood is the role mango consumption plays in the population at risk for type 2

diabetes. This is an area rich for investigation especially with animal and cell culture studies

indicating effects on insulin resistance 65, 84, glycogen metabolism and a potential benefit for

beta-cell pancreatic function 67, 86. Future investigations with mango that focus on well-

characterized populations of people with pre-diabetes will be important for revealing the health

value of mangos in diabetes control.

Mangos and Cardiovascular disease

Cardiovascular diseases account for approximately 17.5 million deaths per year,

representing 31% of all deaths globally. Obesity and diabetes contribute significantly to CVD

risk. Diabetes increases the risk of a cardiovascular event by 3-4 times. Therefore, achieving a

healthy body weight and managing cardio-metabolic risk factors is top priority for reducing risk

for a cardiac event. The role of different fruits is emerging in helping to manage CVD risk

factors; however less is known about mangos.

Reports testing mangiferin, mangiferin-rich extracts, gallotannins, or gallic acid

supplementation on traditional risk factors such as lipid endpoints (ie., TC, TG, HDL) or blood

pressure control have revealed improvements in lipid profiles in rat models 87-90 and reduced

blood pressure elevation in spontaneously hypertensive rats 91, suggesting that mango fruit

consumption may have similar effects, albeit these compounds are supplied in the flesh in lower

amounts. Nonetheless, lower amounts of these compounds may still be important, considering

additivity or synergistic effects when delivered with the full complement of mango

phytochemicals and other fruit components, such as fibers and organic acids. No data in humans

are available at present, however, feeding animals mango juice (Ubá mango, 35 mL/d) for 8

21
weeks resulted in reduced fasting TC, TC:HDL ratio, and TG 64 and 2 months of 1% or 10%

mango supplementation attenuated high fat diet induced increases in total cholesterol and fasting

free fatty acid in mice 65. Although blood pressure has not been assessed after mango fruit

supplementation in either animals or humans, a study was recently published assessing effects of

a pure unripe mango fruit powder marketed as Careless™ on cutaneous blood flow and

endothelial function in ten relatively healthy women (mean age 55 ± 10 y and BMI 25 ± 3

kg/m2). The study tested two doses (100 and 300 mg, no control intervention) and compared

results to baseline over a 6 h period 92 (Table 3). Endothelial dependent relaxation as measured

by EndoPAT™ was not different at 3h from pre-measurement values (baseline) or between doses

in this study. However, blood flow increased approximately 54% at 6 h over baseline in the

100 mg group and 35 % over pre-measurement in the 300 mg group, which implies biological

activity resulting in micro-vascular dilation. For context, the intake of cocoa, known for its

microvascular effects, increased blood flow approximately 70% at 2 h in ten healthy women 93.

Cutaneous microcirculation influences thermoregulation, nutrient and oxygen delivery and

impacts skin health and appearance 94. These data are preliminary but provide insight to the

potential of mangos in vascular function, since stimulation of endothelial nitric oxide synthase

and endothelial cell migration has been reported in cell culture 92, 95 and vaso-relaxation has

been demonstrated with mangiferin and gallotannin in rats and rabbits, respectively, albeit

compounds were not extracted from mango 96, 97.

Risk for thrombotic complications is increased in patients with diabetes and is a main

contributor to higher incidence of CVD and mortality due to ischemic heart disease. Increased

adhesion and aggregation of platelets are characteristic processes promoting thrombosis. Work

with mangos has not concentrated on platelets or a potential for anti-thrombotic actions per se;

22
however, administration of gallotannin (20 mg/kg) to wild type mice blocked ex vivo platelet

aggregation induced by ADP or collagen 98. The same study reported that pre-treating platelets

with gallotannin (1,2,3,4,6-penta-O-galloyl-α-D-glucopyranose) blocked thrombin-induced

release of P-selectin, secretion of ATP and aggregation along with significantly attenuating

ADP- or thrombin- induced decrease in platelet cyclic AMP levels without altering basal or

PGE-1 induced increase in cAMP levels. Interactions of mango with warfarin have also been

reported increasing its anticoagulant effect, which could be due to mangos’ high vitamin A

content increasing blood levels of warfarin or due to other components of mango, such as

gallotannin, adding to the effect of warfarin 99.

Underlying processes fueling CVD risk factors are suggested to be oxidative stress and

chronic low grade inflammation, both which can lead to cellular and tissue damage and

dysfunction. Addressing these imbalances is considered an important part of disease risk

reduction and health. Animal and cell culture studies with mangos, including extracts from all

parts i.e., flesh, leaf, peel, bark, seed, and individual compounds such as mangiferin and gallic

acid and gallotannins show improved oxidative and inflammatory balance as measured by

reduced reactive oxygen species, enhanced endogenous defenses and or reduced cytokine

production. Collectively, the data suggest several potential targets for which mangos may have a

role in reducing CVD risk factors. The data at present suggest exploring in greater detail the

effects of mango fruit consumption on lipid and lipoprotein metabolism and endothelial and

platelet function.

Emerging areas for Mango fruit Health Benefits

23
Brain: Addressing processes underlying disease can have benefits on many systems. Risk factors

for Alzheimer’s disease, for example, are shared with other common chronic diseases. With the

exception of rare cases caused by known genetic mutations, Alzheimer’s develops as a result of

multiple factors rather than a single cause; and develops over several decades. Advancing age is

the greatest risk factor, but Alzheimer’s disease is not part of normal aging. Other risk factors

include family history, apo E genotype, mild cognitive impairment, and cardio-metabolic risk

factors 100. Several studies in cell culture and animal models suggest mangiferin 101-103and

gallotannin 104, 105 have potent neuroprotective activity due to their antioxidant (scavenging ROS

and increasing endogenous defenses) and anti-inflammatory effects, and ability to restore

mitochondrial membrane potential in neuronal cells. Favorable behavioral outcomes have also

been documented in accordance with the biochemical improvements after treatment with the

individual compounds 104-106. These data aid in understanding the potential active compounds in

mango flesh. In an in vitro model of isolated rat brain mitochondria, mango fruit extract inhibited

amyloid beta peptide-induced mitochondrial toxicity as measured decreased ROS formation,

mitochondrial membrane potential collapse, mitochondrial swelling, and cytochrome c release

107
. In an animal model studying cognitive performance using step down passive avoidance task

and elevated plus maze tasks, seven days treatment with mango fruit extract reversed aging- and

scopolamine- induced memory deficits as assessed in both paradigms 108 (Table 5). Likewise, in

a model of mild cognitive impairment, two weeks pre-treatment and one week post-bilateral

injection with AF64A, mango fruit extract (12.5-200 mg/kg) improved memory and oxidative

stress / defense status; and at the 50 and 200 mg/kg doses, increased cholinergic neurons density

in the hippocampus 109. Collectively, the data support actions of mango fruit in brain health with

insight to the potentially active components. Further research is essential to elucidate active

24
ingredients in the flesh, including active metabolites relative to mechanism of action;

notwithstanding, the need to demonstrate behavioral outcomes in humans, in which no data are

available currently.

Skin: The role of ROS producing oxidative stress and damage in skin aging has become

increasingly appreciated over the last several decades. ROS are generated in normal

physiological processes and increased under exaggerated or stressed physiological conditions,

such as during mitochondria-catalyzed electron transport reactions and by neutrophils and

macrophages during inflammation, respectively. ROS are also generated during environmental

exposures such as to irradiation by UV light (sun light). The skin is a major environmental

interface for the body placing it at continual risk for accumulated ROS, particularly from

excessive UV exposure that can overwhelm endogenous defenses and damage cellular

components than lead to “photo-aged” skin, skin cancer and other cutaneous inflammatory

conditions 110. The skin contains various mechanisms for oxidative defense; however, enhancing

protection through the intake of antioxidant-rich foods has attracted attention in recent years.

Mangos contain both hydrophilic and lipophilic compounds with antioxidant properties

ideal for protecting lipid-rich membranes and aqueous cellular components. Few studies have

been published on mangos and skin health; however, the data look promising warranting further

research. In a UVB-induced skin aging model, mango extract (100 mg/kg/d) inhibited increases

in epidermal thickness and epidermal hypertrophy, and protected against UVB-induced collagen

fiber damage as well as increased collagen bundles 111 (Table 5). Collagen is an important

component of skin tissue providing stability and structural integrity. Degradation of collagen is

considered a major contributor to wrinkle formation and skin appearance. Therefore, reducing

25
collagen damage and loss and or stimulating synthesis would be advantageous in maintaining

healthy, younger looking skin. The protective effects of mango is thought to be due to its

antioxidant capability and reducing damaging ROS 112, 113, and this effect appears to be

associated with ethanol fractions of the mango fruit 113. Likewise, studies with mangiferin alone

indicate reduced oxidative stress, decreased activation of cellular stress pathways ie., ERK,

MEK, JNK, AP-1, and decreased synthesis of matrix metalloproteinases MMP 112, 114, which is

involved in collagen degradation.

Intestinal health: Ulcerative colitis is a form inflammatory bowel disease characterized by

overproduction of ROS relative to endogenous defenses and pro-inflammatory cytokines leading

to chronic inflammation and mucosal damage in the large intestine 115. Ulcerative colitis

development is influenced by a number of factors including genetic predisposition, immune

dysregulation, the composition of the microbiome and various environmental factors, including

the diet 116, 117. As described in various parts of this paper, a variety of cell culture and animal

models of disease, including models of colitis and gastritis, have shown that mangiferin,

neomangiferin and gallotannin as well as extracts rich in these compounds from non-edible, by-

products of mango, reduce ROS, in part by inducing the expression of Nrf2 and HO-1 along with

downregulating NF-κB via suppression of stress response pathways that would otherwise lead to

a robust inflammatory response characterized by marked increases inflammatory cytokines,

chemokines and iNOS, COX-2 among others 118-125. Extending this research to better understand

the role of mango fruit actions in inflammation-based intestinal diseases, mango fruit (Keitt cv)

beverages were prepared from homogenized flesh and fed to dextran sodium sulfate (DSS)

treated rats to induce chronic colitis. Extracts from the same fruit were prepared and molecular

mechanisms investigated in lipopolysaccharide (LPS) stimulated non-cancer colon cells 75, 76

26
(Table 5). In two studies, each studying mango in cells and animals, reported mango beverages

or extracts from the fruit beverages significantly attenuated gene and protein expression of pro-

inflammatory cytokines as well as reduced expression of upstream signaling proteins including

PI3K, AKT, and mTOR, whereas, miR-126 was upregulated by the mango treatment.

Proliferation indexes were reduced compared to control; however, ulceration scores were not

reduced. In silico docking studies suggested mango extracts and gallic acid docked favorably

into the IGF-1R ATP binding pocket; results that were corroborated by cell studies showing

reduced expression of IGF-1R mRNA by 29% (10 mg/L GAE of mango extract) and by 39%

with 4 mg/L of gallic acid. IGF-1R is involved in mTOR and MAPK pathways influencing

inflammation and proliferation endpoints.

The DSS-induced colitis rodent model is a standard model that mimics changes in

epithelial cell permeability and acute inflammation in the colon of humans with colitis. Different

levels of severity can be induced making it a useful pre-clinical model for testing the therapeutic

potential of agents to prevent or treat human ulcerative colitis. While much of the earlier work

focused on the efficacy of individual compounds (ie., gallic acid, mangiferin), the results of this

recent work demonstrates biologically relevant activity with mango fruit beverages. The results

are promising and support further work, particularly related to understanding the relationship

between mangos’ effects on intestinal inflammation and improvements in the proliferation index

but not ulceration scores. It may be that dose and treatment duration may be influencing results

or the role of mango maybe more preventative and best used for managing disease process rather

than wound healing. Continued research in the area will undoubtedly uncover these details.

Summary and Conclusions

27
 Mangos contribute a number of valuable essential nutrients and exclusive bioactive

components to the diet. However, bioavailability, metabolism and pharmacokinetic parameters

of mango polyphenols have not been studied in detail and future studies can fill gaps in this area,

which can guide clinical study design and support evidence associated with mango health

benefits. Epidemiology indicates mango consumption is associated with better nutrients intake

and diet quality 126. In vitro and in vivo animal studies have indicated that mangos and their

various extracts and individual components have anti-inflammatory and anti-oxidative

properties, which serve as major targets for controlling the dysfunction and damage that these

imbalances create leading to disease. Concerns about mango as a tropical fruit contributing to

obesity and diabetes are outdated. The current research suggests otherwise, with human studies

reporting benefits in glycemic control, possibly through improvements in insulin action and or

glycogen synthesis bringing to bare the importance of dose (amount of mango consumed) and

role of fructose. Newer work in mice has revealed benefits on the microbiome which future

studies in humans may uncover as a critical factor in mango associated inflammation- and

metabolic- benefits; locally in the bowel and systemically. Work on blood flow indicate potential

benefits for vascular health and skin health, increasing cutaneous flow bringing protective

nutrients to skin for fighting excess ROS. Likewise, eating mangos for systemic and gut health

may also be important for brain health and deserves more investigation to reveal the benefits.

Figure 2 depicts the role mangos may play in human health. The review of the science provides

insight for future directions and warrants follow up research in humans.

Acknowledgements

All authors have read and approved the final manuscript.

28
References:

1. USDA, Scientific Report of the 2015 Dietary Guidelines Advisory Committee.

http://www.health.gov/dietaryguidelines/2015-scientific-report/PDFs/Scientific-Report-of-the-
2015-Dietary-Guidelines-Advisory-Committee.pdf. Accessed on December 19, 2016.
2. E. V. Fomenko and Y. Chi, Mangiferin modulation of metabolism and metabolic syndrome,
BioFactors, 2016, 42, 492-503.
3. M. H. A. Jahurul, I. S. M. Zaidul, K. Ghafoor, F. Y. Al-Juhaimi, K.-L. Nyam, N. A. N. Norulaini, F.
Sahena and A. K. Mohd Omar, Mango (Mangifera indica L.) by-products and their valuable
components: A review, Food Chem., 2015, 183, 173-180.
4. R. K. Khurana, R. Kaur, S. Lohan, K. K. Singh and B. Singh, Mangiferin: a promising anticancer
bioactive, Pharm Pat Anal, 2016, 5, 169-181.
5. K. A. Shah, M. B. Patel, R. J. Patel and P. K. Parmar, Mangifera Indica (Mango), Pharmacogn Rev.,
2010, 4, 42-48.
6. FAOSTAT, World Fruit Production (www.fao.org) 2013-2014. Accessed on Jan 7, 2017.
7. Mango.org, http://www.mango.org/Choosing-Using-Mangos/Mango-Varieties. Accessed on
October 5, 2016.
8. R. N. Tharanathan, H. M. Yashoda and T. N. Prabha, Mango (Mangifera indica L.), “The King of
Fruits”—An Overview, Food Rev. Int., 2006, 22, 95-123.
9. A. P. Medlicott and A. K. Thompson, Analysis of sugars and organic acids in ripening mango fruits
(Mangifera indica L. var Keitt) by high performance liquid chromatography, J. Sci. Food Agric.,
1985, 36, 561-566.
10. M. Ueda, K. Sasaki, N. Utsunomiya, K. Inaba and Y. Shimabayashi, Changes in Physical and
Chemical Properties during Maturation of Mango Fruit (Mangifera indica L. 'Irwin') Cultured in a
Plastic Greenhouse, Food Science and Technology International, Tokyo, 2000, 6, 299-305.
11. M. Masibo and Q. He, Major Mango Polyphenols and Their Potential Significance to Human
Health, Comprehensive Reviews in Food Science and Food Safety, 2008, 7, 309-319.
12. P. Mattila and J. Kumpulainen, Determination of Free and Total Phenolic Acids in Plant-Derived
Foods by HPLC with Diode-Array Detection, J. Agric. Food. Chem., 2002, 50, 3660-3667.
13. W. R. Russell, A. Labat, L. Scobbie, G. J. Duncan and G. G. Duthie, Phenolic acid content of fruits
commonly consumed and locally produced in Scotland, Food Chem., 2009, 115, 100-104.
14. A. M. Abbasi, X. Guo, X. Fu, L. Zhou, Y. Chen, Y. Zhu, H. Yan and R. H. Liu, Comparative
Assessment of Phenolic Content and in Vitro Antioxidant Capacity in the Pulp and Peel of Mango
Cultivars, Inter J Mol Sci, 2015, 16, 13507-13527.
15. H. Palafox-Carlos, E. M. Yahia and G. A. González-Aguilar, Identification and quantification of
major phenolic compounds from mango (Mangifera indica, cv. Ataulfo) fruit by HPLC–DAD–
MS/MS-ESI and their individual contribution to the antioxidant activity during ripening, Food
Chem., 2012, 135, 105-111.
16. Y. Kim, A. J. Lounds-Singleton and S. T. Talcott, Antioxidant phytochemical and quality changes
associated with hot water immersion treatment of mangoes (Mangifera indica L.), Food Chem.,
2009, 115, 989-993.
17. N. Ongphimai, S. Lilitchan, K. B. Aryusuk, A; and K. Krisnangkura, Phenolic Acids Content and
Antioxidant Capacity of Fruit Extracts from Thailand, Chiang Mai J. Sci., 2013, 40, 636-642.
18. S. Poovarodom, R. Haruenkit, S. Vearasilp, J. Namiesnik, M. Cvikrová, O. Martincová, A. Ezra, M.
Suhaj, P. Ruamsuke and S. Gorinstein, Comparative characterisation of durian, mango and
avocado, Int. J. Food Sci. Tech., 2010, 45, 921-929.
29
19. M. P. Cano and B. de Ancos, Carotenoid and Carotenoid Ester Composition in Mango Fruit As
Influenced by Processing Method, J. Agric. Food. Chem., 1994, 42, 2737-2742.
20. S. Varakumar, Y. S. Kumar and O. V. S. Reddy, Carotenoid composition of mango (mangifera
indica l.) wine and its antioxidant activity, J. Food Biochem., 2011, 35, 1538-1547.
21. D. B. Rodriguez-Amaya, E. B. Rodriguez and J. Amaya-Farfan, Advances in Food Carotenoid
Research: Chemical and Technological Aspects, Implications in Human Health, Mal J Nutr, 2006,
12, 101-121.
22. J. Ornelas-Paz Jde, E. M. Yahia and A. Gardea-Bejar, Identification and quantification of
xanthophyll esters, carotenes, and tocopherols in the fruit of seven Mexican mango cultivars by
liquid chromatography-atmospheric pressure chemical ionization-time-of-flight mass
spectrometry [LC-(APcI(+))-MS], J. Agric. Food. Chem., 2007, 55, 6628-6635.
23. F. C. Petry and A. Z. Mercadante, Composition by LC-MS/MS of New Carotenoid Esters in Mango
and Citrus, J. Agric. Food. Chem., 2016, 64, 8207-8224.
24. A. Z. Mercadante, D. B. Rodriguez-Amaya and G. Britton, HPLC and Mass Spectrometric Analysis
of Carotenoids from Mango, J. Agric. Food. Chem., 1997, 45, 120-123.
25. E. M. Yahia, J. J. Ornelas-Paz and A. Gardea, Extraction, separation and partial identification of
´ataulfo´ mango fruit carotenoids. Conference Proceedings, ActaHortic., 2006, 333-338.
26. J. A. Manthey and P. Perkins-Veazie, Influences of Harvest Date and Location on the Levels of β-
Carotene, Ascorbic Acid, Total Phenols, the in Vitro Antioxidant Capacity, and Phenolic Profiles
of Five Commercial Varieties of Mango (Mangifera indica L.), J. Agric. Food. Chem., 2009, 57,
10825-10830.
27. S. Haque, P. Begum, M. Khatun and S. Nazrul Islam, Total Carotenoid Content in Some Mango
(Mangifera Indica) Varieties of Bangladesh, IJPSR, 2015, 6, 4875-4878.
28. J. S. Negi, V. K. Bisht, P. Singh, M. S. M. Rawat and G. P. Joshi, Naturally Occurring Xanthones:
Chemistry and Biology, J. Appl. Chem., 2013, 2013, 9.
29. L. M. Vieira and A. Kijjoa, Naturally-occurring xanthones: recent developments, Curr. Med.
Chem., 2005, 12, 2413-2446.
30. F. Luo, Q. Lv, Y. Zhao, G. Hu, G. Huang, J. Zhang, C. Sun, X. Li and K. Chen, Quantification and
Purification of Mangiferin from Chinese Mango (Mangifera indica L.) Cultivars and Its Protective
Effect on Human Umbilical Vein Endothelial Cells under H2O2-induced Stress, Inter. J. Mol. Sci.,
2012, 13, 11260.
31. J. E. Ramirez, R. Zambrano, B. Sepulveda and M. J. Simirgiotis, Antioxidant properties and
hyphenated HPLC-PDA-MS profiling of Chilean Pica mango fruits (Mangifera indica L. Cv.
piqueno), Molecules, 2013, 19, 438-458.
32. S. M. R. Ribeiro, L. C. A. Barbosa, J. H. Queiroz, M. Knödler and A. Schieber, Phenolic compounds
and antioxidant capacity of Brazilian mango (Mangifera indica L.) varieties, Food Chem., 2008,
110, 620-626.
33. M. Kajdžanoska, V. Gjamovski and M. Stefova, HPLC-DAD-ESI-MSn identification of phenolic
compounds in cultivated strawberries from Macedonia, Macedonian J Chem. Chemical Eng. ,
2010, 29, 14.
34. J. Kolniak-Ostek, A. Z. Kucharska, A. Sokol-Letowska and I. Fecka, Characterization of phenolic
compounds of thorny and thornless blackberries, J. Agric. Food. Chem., 2015, 63, 3012-3021.
35. M. Sugiyama, T. Katsube, A. Koyama and H. Itamura, Varietal differences in the flavonol content
of mulberry (Morus spp.) leaves and genetic analysis of quercetin 3-(6-malonylglucoside) for
component breeding, J. Agric. Food. Chem., 2013, 61, 9140-9147.

30
36. N. Berardini, R. Fezer, J. Conrad, U. Beifuss, R. Carle and A. Schieber, Screening of mango
(Mangifera indica L.) cultivars for their contents of flavonol O- and xanthone C-glycosides,
anthocyanins, and pectin, J. Agric. Food. Chem., 2005, 53, 1563-1570.
37. J. Lako, V. C. Trenerry, M. Wahlqvist, N. Wattanapenpaiboon, S. Sotheeswaran and R. Premier,
Phytochemical flavonols, carotenoids and the antioxidant properties of a wide selection of Fijian
fruit, vegetables and other readily available foods, Food Chem., 2007, 101, 1727-1741.
38. G. R. Beecher, Overview of Dietary Flavonoids: Nomenclature, Occurrence and Intake, J. Nutr.,
2003, 133, 3248S-3254S.
39. I. C. Arts, B. van de Putte and P. C. Hollman, Catechin contents of foods commonly consumed in
The Netherlands. 1. Fruits, vegetables, staple foods, and processed foods, J. Agric. Food. Chem.,
2000, 48, 1746-1751.
40. O. Osorio-Esquivel, V. Cortés-Viguri, L. Garduño-Siciliano, A. Ortiz-Moreno and M. Sánchez-
Pardo, Hypolipidemic Activity of Microwave-Dehydrated Mango (Mangifera indica L.) Powder in
Mice Fed a Hypercholesterolemic Diet., J. Biomed. Sci. Eng., 2014, 7, 809-817.
41. L. Gu, M. A. Kelm, J. F. Hammerstone, G. Beecher, J. Holden, D. Haytowitz, S. Gebhardt and R. L.
Prior, Concentrations of proanthocyanidins in common foods and estimations of normal
consumption, J. Nutr., 2004, 134, 613-617.
42. A. E. Hagerman, Hydrolyzable Tannin Structural Chemistry, Tannin Handbook
(http://www.users.muohio.edu/hagermae/tannin.pdf). 2002, 1-8.
43. N. Berardini, R. Carle and A. Schieber, Characterization of gallotannins and benzophenone
derivatives from mango (Mangifera indica L. cv. 'Tommy Atkins') peels, pulp and kernels by high-
performance liquid chromatography/electrospray ionization mass spectrometry, Rapid
Commun. Mass Spectrom., 2004, 18, 2208-2216.
44. B. G. Oliveira, H. B. Costa, J. A. Ventura, T. P. Kondratyuk, M. E. Barroso, R. M. Correia, E. F.
Pimentel, F. E. Pinto, D. C. Endringer and W. Romao, Chemical profile of mango (Mangifera
indica L.) using electrospray ionisation mass spectrometry (ESI-MS), Food Chem., 2016, 204, 37-
45.
45. J. T. Pierson, G. R. Monteith, S. J. Roberts-Thomson, R. G. Dietzgen, M. J. Gidley and P. N. Shaw,
Phytochemical extraction, characterisation and comparative distribution across four mango
(Mangifera indica L.) fruit varieties, Food Chem., 2014, 149, 253-263.
46. M. Léchaudel and J. Joas, An overview of preharvest factors influencing mango fruit growth,
quality and postharvest behaviour, Brazilian J.Plant Physiol., 2007, 19, 287-298.
47. A. A. Kader, Pre- and postharvest factors affecting fresh produce quality, nutritional value, and
implications for human health., Proceedings of the International Congress Food Production and
the Quality of Life, Sassari (Italy), 2002, 1, 109-119.
48. W. Stahl, H. van den Berg, J. Arthur, A. Bast, J. Dainty, R. M. Faulks, C. Gartner, G. Haenen, P.
Hollman, B. Holst, F. J. Kelly, M. C. Polidori, C. Rice-Evans, S. Southon, T. van Vliet, J. Vina-Ribes,
G. Williamson and S. B. Astley, Bioavailability and metabolism, Mol. Aspects Med., 2002, 23, 39-
100.
49. R. J. Wood, in Encyclopedia of human nutrition, eds. C. B.;, P. A.; and A. L., Oxford: Elsevier Ltd,
2nd edn., 2005.
50. D. M. Deming and J. Erdman, J. W., Mammalian carotenoid absorption and metabolism, Pure
Appl. Chem., 1999, 71, 2213-2223.
51. E. Reboul, Absorption of Vitamin A and Carotenoids by the Enterocyte: Focus on Transport
Proteins, Nutrients, 2013, 5, 3563.
52. I. Epriliati, B. D'Arcy and M. Gidley, Nutriomic analysis of fresh and processed fruit products. 1.
During in vitro digestions, J. Agric. Food. Chem., 2009, 57, 3363-3376.
31
53. I. Epriliati, B. D’Arcy and M. Gidley, Nutriomic Analysis of Fresh and Processed Fruit Products. 2.
During in Vitro Simultaneous Molecular Passages Using Caco-2 Cell Monolayers, J. Agric. Food.
Chem., 2009, 57, 3377-3388.
54. J. Ornelas-Paz Jde, E. M. Yahia, A. A. Gardea and M. L. Failla, Carotenoid Composition in Ataulfo
Mango and their Bioavailability and Bioconversion to Vitamin A. , ActaHortic., 2010, DOI:
10.17660/ActaHortic.2010.877.170, 1245-1252.
55. D. Y. Low, B. D'Arcy and M. J. Gidley, Mastication effects on carotenoid bioaccessibility from
mango fruit tissue, Food Res. Int., 2015, 67, 238-246.
56. D. Y. Low, M. P. Hodson, B. A. Williams, B. R. D'Arcy and M. J. Gidley, Microbial
biotransformation of polyphenols during in vitro colonic fermentation of masticated mango and
banana, Food Chem., 2016, 207, 214-222.
57. F. J. Blancas-Benitez, G. Mercado-Mercado, A. E. Quiros-Sauceda, E. Montalvo-Gonzalez, G. A.
Gonzalez-Aguilar and S. G. Sayago-Ayerdi, Bioaccessibility of polyphenols associated with dietary
fiber and in vitro kinetics release of polyphenols in Mexican 'Ataulfo' mango (Mangifera indica
L.) by-products, Food Funct, 2015, 6, 859-868.
58. X. Liu, J. Bi, H. Xiao and D. J. McClements, Enhancement of Nutraceutical Bioavailability using
Excipient Nanoemulsions: Role of Lipid Digestion Products on Bioaccessibility of Carotenoids and
Phenolics from Mangoes, J. Food Sci., 2016, 81, N754-761.
59. J. Ornelas-Paz Jde, E. M. Yahia and A. A. Gardea, Bioconversion Efficiency of b-Carotene from
Mango Fruit and Carrots in Vitamin A, Ameri. J. Agric. Bio. Sci., 2010, 5, 301-308.
60. I. Gouado, F. J. Schweigert, R. A. Ejoh, M. F. Tchouanguep and J. V. Camp, Systemic levels of
carotenoids from mangoes and papaya consumed in three forms (juice, fresh and dry slice), Eur.
J. Clin. Nutr., 2007, 61, 1180-1188.
61. R. C. Barnes, K. A. Krenek, B. Meibohm, S. U. Mertens-Talcott and S. T. Talcott, Urinary
metabolites from mango (Mangifera indica L. cv. Keitt) galloyl derivatives and in vitro hydrolysis
of gallotannins in physiological conditions, Mol. Nutr. Food Res., 2016, 60, 542-550.
62. J. C. Chan, V. Malik, W. Jia, T. Kadowaki, C. S. Yajnik, K. H. Yoon and F. B. Hu, Diabetes in Asia:
epidemiology, risk factors, and pathophysiology, JAMA, 2009, 301, 2129-2140.
63. B. Burton-Freeman, Postprandial metabolic events and fruit-derived phenolics: a review of the
science, Br. J. Nutr., 2010, 104 Suppl 3, S1-14.
64. D. I. Gomes Natal, M. E. de Castro Moreira, M. Soares Miliao, L. Dos Anjos Benjamin, M. I. de
Souza Dantas, S. Machado Rocha Ribeiro and H. Stampini Duarte Martino, Uba mango juices
intake decreases adiposity and inflammation in high-fat diet-induced obese Wistar rats,
Nutrition, 2016, 32, 1011-1018.
65. E. A. Lucas, W. Li, S. K. Peterson, A. Brown, S. Kuvibidila, P. Perkins-Veazie, S. L. Clarke and B. J.
Smith, Mango modulates body fat and plasma glucose and lipids in mice fed a high-fat diet, Br. J.
Nutr., 2011, 106, 1495-1505.
66. B. Ojo, G. D. El-Rassi, M. E. Payton, P. Perkins-Veazie and S. Clarke, Mango Supplementation
Modulates Gut Microbial Dysbiosis and Short-Chain Fatty Acid Production Independent of Body
Weight Reduction in C57BL/6 Mice Fed a High-Fat Diet, J. Nutr., 2016, 146, 1483-1491.
67. G. F. Perpétuo and J. M. Salgado, Effect of mango (Mangifera indica, L.) ingestion on blood
glucose levels of normal and diabetic rats, Plant Foods Hum. Nutr., 2003, 58, 1-12.
68. Z. Contractor, F. Hussain and A. Jabbar, Postprandial glucose response to mango, banana and
sapota, J. Pak. Med. Assoc., 1999, 49, 215-216.
69. A. E. Edo, A. Eregie, O. S. Adediran and A. E. Ohwovoriole, Glycaemic response to some
commonly eaten fruits in type 2 diabetes mellitus, West Afr. J. Med., 2011, 30, 94-98.

32
70. L. Elizondo-Montemayor, C. Hernandez-Brenes, P. A. Ramos-Parra, D. Moreno-Sanchez, B.
Nieblas, A. M. Rosas-Perez and A. C. Lamadrid-Zertuche, High hydrostatic pressure processing
reduces the glycemic index of fresh mango puree in healthy subjects, Food Funct, 2015, 6, 1352-
1360.
71. S. F. Evans, M. Meister, M. Mahmood, H. Eldoumi, S. Peterson, P. Perkins-Veazie, S. L. Clarke, M.
Payton, B. J. Smith and E. A. Lucas, Mango Supplementation Improves Blood Glucose in Obese
Individuals, Nutrition and Metabolic Insights, 2014, 7, 77-84.
72. K. Fatema, L. Ali, M. H. Rahman, S. Parvin and Z. Hassan, Serum glucose and insulin response to
mango and papaya in type 2 diabetic subjects, Nutr. Res., 2003, 23, 9-14.
73. M. T. Guevarra and L. N. Panlasigui, Blood glucose responses of diabetes mellitus type II patients
to some local fruits, Asia Pac. J. Clin. Nutr., 2000, 9, 303-308.
74. C. Roongpisuthipong, S. Banphotkasem, S. Komindr and V. Tanphaichitr, Postprandial glucose
and insulin responses to various tropical fruits of equivalent carbohydrate content in non-
insulin-dependent diabetes mellitus, Diabetes Res. Clin. Pract., 1991, 14, 123-131.
75. H. Kim, N. Banerjee, I. Ivanov, C. M. Pfent, K. R. Prudhomme, W. H. Bisson, R. H. Dashwood, S. T.
Talcott and S. U. Mertens-Talcott, Comparison of anti-inflammatory mechanisms of mango
(Mangifera Indica L.) and pomegranate (Punica Granatum L.) in a preclinical model of colitis,
Mol. Nutr. Food Res., 2016, 60, 1912-1923.
76. H. Kim, N. Banerjee, R. C. Barnes, C. M. Pfent, S. T. Talcott, R. H. Dashwood and S. U. Mertens-
Talcott, Mango polyphenolics reduce inflammation in intestinal colitis-involvement of the miR-
126/PI3K/AKT/mTOR axis in vitro and in vivo, Mol. Carcinog., 2017, 56, 197-207.
77. S. Prasad, N. Kalra and Y. Shukla, Hepatoprotective effects of lupeol and mango pulp extract of
carcinogen induced alteration in Swiss albino mice, Mol. Nutr. Food Res., 2007, 51, 352-359.
78. S. Prasad, N. Kalra, M. Singh and Y. Shukla, Protective effects of lupeol and mango extract
against androgen induced oxidative stress in Swiss albino mice, Asian J Androl, 2008, 10, 313-
318.
79. S. S. Panda, M. Chand, R. Sakhuja and S. C. Jain, Xanthones as potential antioxidants, Curr. Med.
Chem., 2013, 20, 4481-4507.
80. A. Vyas, K. Syeda, A. Ahmad, S. Padhye and F. H. Sarkar, Perspectives on medicinal properties of
mangiferin, Mini Rev. Med. Chem., 2012, 12, 412-425.
81. F. F. Anhe, G. Pilon, D. Roy, Y. Desjardins, E. Levy and A. Marette, Triggering Akkermansia with
dietary polyphenols: A new weapon to combat the metabolic syndrome?, Gut Microbes, 2016, 7,
146-153.
82. I. Magnusson, D. L. Rothman, L. D. Katz, R. G. Shulman and G. I. Shulman, Increased rate of
gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study, J. Clin.
Invest., 1992, 90, 1323-1327.
83. G. Velho, K. F. Petersen, G. Perseghin, J. H. Hwang, D. L. Rothman, M. E. Pueyo, G. W. Cline, P.
Froguel and G. I. Shulman, Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-
2) subjects, J. Clin. Invest., 1996, 98, 1755-1761.
84. C. G. Mohan, G. L. Viswanatha, G. Savinay, C. E. Rajendra and P. D. Halemani, 1,2,3,4,6 Penta-O-
galloyl-beta-d-glucose, a bioactivity guided isolated compound from Mangifera indica inhibits
11beta-HSD-1 and ameliorates high fat diet-induced diabetes in C57BL/6 mice, Phytomedicine,
2013, 20, 417-426.
85. S. Saleh, N. El-Maraghy, E. Reda and W. Barakat, Modulation of diabetes and dyslipidemia in
diabetic insulin-resistant rats by mangiferin: role of adiponectin and TNF-alpha, An. Acad. Bras.
Cienc., 2014, 86, 1935-1948.

33
86. H. L. Wang, C. Y. Li, B. Zhang, Y. D. Liu, B. M. Lu, Z. Shi, N. An, L. K. Zhao, J. J. Zhang, J. K. Bao and
Y. Wang, Mangiferin facilitates islet regeneration and beta-cell proliferation through
upregulation of cell cycle and beta-cell regeneration regulators, Int J Mol Sci, 2014, 15, 9016-
9035.
87. M. Akila and H. Devaraj, Synergistic effect of tincture of Crataegus and Mangifera indica L.
extract on hyperlipidemic and antioxidant status in atherogenic rats, Vascul. Pharmacol., 2008,
49, 173-177.
88. C. L. Hsu and G. C. Yen, Effect of gallic acid on high fat diet-induced dyslipidaemia,
hepatosteatosis and oxidative stress in rats, Br. J. Nutr., 2007, 98, 727-735.
89. S. Muruganandan, K. Srinivasan, S. Gupta, P. K. Gupta and J. Lal, Effect of mangiferin on
hyperglycemia and atherogenicity in streptozotocin diabetic rats, J. Ethnopharmacol., 2005, 97,
497-501.
90. H. S. Parmar and A. Kar, Possible amelioration of atherogenic diet induced dyslipidemia,
hypothyroidism and hyperglycemia by the peel extracts of Mangifera indica, Cucumis melo and
Citrullus vulgaris fruits in rats, BioFactors, 2008, 33, 13-24.
91. J. C. Liu, F. L. Hsu, J. C. Tsai, P. Chan, J. Y. Liu, G. N. Thomas, B. Tomlinson, M. Y. Lo and J. Y. Lin,
Antihypertensive effects of tannins isolated from traditional Chinese herbs as non-specific
inhibitors of angiontensin converting enzyme, Life Sci., 2003, 73, 1543-1555.
92. A. Gerstgrasser, S. Rochter, D. Dressler, C. Schon, C. Reule and S. Buchwald-Werner, In Vitro
Activation of eNOS by Mangifera indica (Careless) and Determination of an Effective Dosage in a
Randomized, Double-Blind, Human Pilot Study on Microcirculation, Planta Med., 2016, 82, 298-
304.
93. K. Neukam, W. Stahl, H. Tronnier, H. Sies and U. Heinrich, Consumption of flavanol-rich cocoa
acutely increases microcirculation in human skin, Eur. J. Nutr., 2007, 46, 53-56.
94. E. Boelsma, L. P. van de Vijver, R. A. Goldbohm, I. A. Klopping-Ketelaars, H. F. Hendriks and L.
Roza, Human skin condition and its associations with nutrient concentrations in serum and diet,
Am. J. Clin. Nutr., 2003, 77, 348-355.
95. N. H. Daud, C. S. Aung, A. K. Hewavitharana, A. S. Wilkinson, J.-T. Pierson, S. J. Roberts-Thomson,
P. N. Shaw, G. R. Monteith, M. J. Gidley and M.-O. Parat, Mango Extracts and the Mango
Component Mangiferin Promote Endothelial Cell Migration, J. Agric. Food. Chem., 2010, 58,
5181-5186.
96. G. Beretta, G. Rossoni, N. A. Santagati and R. M. Facino, Anti-ischemic activity and endothelium-
dependent vasorelaxant effect of hydrolysable tannins from the leaves of Rhus coriaria (Sumac)
in isolated rabbit heart and thoracic aorta, Planta Med., 2009, 75, 1482-1488.
97. S. Oshimi, K. Zaima, Y. Matsuno, Y. Hirasawa, T. Iizuka, H. Studiawan, G. Indrayanto, N. C. Zaini
and H. Morita, Studies on the constituents from the fruits of Phaleria macrocarpa, J. Nat. Med.,
2008, 62, 207-210.
98. R. Perveen, K. Funk, J. Thuma, S. Wulf Ridge, Y. Cao, J. W. Akkerman, X. Chen and H. Akbar, A
novel small molecule 1,2,3,4,6-penta-O-galloyl-alpha-D-glucopyranose mimics the antiplatelet
actions of insulin, PLoS One, 2011, 6, e26238.
99. J. Monterrey-Rodriguez, Interaction between warfarin and mango fruit, Ann. Pharmacother.,
2002, 36, 940-941.
100. Alzheimer’s Disease Facts and Figures. Alzheimer's and Dementia
https://www.alz.org/downloads/Facts_Figures_2014.pdf Accessed on Jan 23, 2017).
101. H. S. Bhatia, E. Candelario-Jalil, A. C. de Oliveira, O. A. Olajide, G. Martinez-Sanchez and B. L.
Fiebich, Mangiferin inhibits cyclooxygenase-2 expression and prostaglandin E2 production in
activated rat microglial cells, Arch. Biochem. Biophys., 2008, 477, 253-258.
34
102. M. R. Campos-Esparza, M. V. Sanchez-Gomez and C. Matute, Molecular mechanisms of
neuroprotection by two natural antioxidant polyphenols, Cell Calcium, 2009, 45, 358-368.
103. Y. Lemus-Molina, M. V. Sanchez-Gomez, R. Delgado-Hernandez and C. Matute, Mangifera indica
L. extract attenuates glutamate-induced neurotoxicity on rat cortical neurons, Neurotoxicology,
2009, 30, 1053-1058.
104. H. Fujiwara, M. Tabuchi, T. Yamaguchi, K. Iwasaki, K. Furukawa, K. Sekiguchi, Y. Ikarashi, Y. Kudo,
M. Higuchi, T. C. Saido, S. Maeda, A. Takashima, M. Hara, N. Yaegashi, Y. Kase and H. Arai, A
traditional medicinal herb Paeonia suffruticosa and its active constituent 1,2,3,4,6-penta-O-
galloyl-beta-D-glucopyranose have potent anti-aggregation effects on Alzheimer's amyloid beta
proteins in vitro and in vivo, J. Neurochem., 2009, 109, 1648-1657.
105. G. L. Viswanatha, H. Shylaja and C. G. Mohan, Alleviation of transient global
ischemia/reperfusion-induced brain injury in rats with 1,2,3,4,6-penta-O-galloyl-beta-d-
glucopyranose isolated from Mangifera indica, Eur. J. Pharmacol., 2013, 720, 286-293.
106. G. L. Pardo Andreu, N. Maurmann, G. K. Reolon, C. B. de Farias, G. Schwartsmann, R. Delgado
and R. Roesler, Mangiferin, a naturally occurring glucoxilxanthone improves long-term object
recognition memory in rats, Eur. J. Pharmacol., 2010, 635, 124-128.
107. A. Salimi, A. Ayatollahi, E. Seydi, N. Khomeisi and J. Pourahmad, Direct toxicity of amyloid beta
peptide on rat brain mitochondria: preventive role of Mangifera indica and Juglans regia,
Toxicol. Environ. Chem., 2015, 97, 1057-1070.
108. S. Kumar, K. K. Maheshwari and V. Singh, Effects of Mangifera indica fruit extract on cognitive
deficits in mice, J. Environ. Biol., 2009, 30, 563-566.
109. J. Wattanathorn, S. Muchimapura, W. Thukham-Mee, K. Ingkaninan and S. Wittaya-Areekul,
Mangifera indica fruit extract improves memory impairment, cholinergic dysfunction, and
oxidative stress damage in animal model of mild cognitive impairment, Oxid. Med. Cell. Longev.,
2014, 2014, 132097.
110. R. T. Narendhirakannan and M. A. C. Hannah, Oxidative Stress and Skin Cancer: An Overview,
Indian J. Clin. Biochem., 2013, 28, 110-115.
111. J. H. Song, E. Y. Bae, G. Choi, J. W. Hyun, M. Y. Lee, H. W. Lee and S. Chae, Protective effect of
mango (Mangifera indica L.) against UVB-induced skin aging in hairless mice, Photodermatol.
Photoimmunol. Photomed., 2013, 29, 84-89.
112. S. Chae, M. J. Piao, K. A. Kang, R. Zhang, K. C. Kim, U. J. Youn, K. W. Nam, J. H. Lee and J. W.
Hyun, Inhibition of matrix metalloproteinase-1 induced by oxidative stress in human
keratinocytes by mangiferin isolated from Anemarrhena asphodeloides, Biosci. Biotechnol.
Biochem., 2011, 75, 2321-2325.
113. C. Ronpirin, N. Pattarachotanant and T. Tencomnao, Protective Effect of Mangifera indica Linn.,
Cocos nucifera Linn., and Averrhoa carambola Linn. Extracts against Ultraviolet B-Induced
Damage in Human Keratinocytes, Evid. Based Complement. Alternat. Med., 2016, 2016,
1684794.
114. H.-S. Kim, J. H. Song, U. J. Youn, J. W. Hyun, W. S. Jeong, M. Y. Lee, H. J. Choi, H.-K. Lee and S.
Chae, Inhibition of UVB-induced wrinkle formation and MMP-9 expression by mangiferin
isolated from Anemarrhena asphodeloides, Eur. J. Pharmacol., 2012, 689, 38-44.
115. R. J. Xavier and D. K. Podolsky, Unravelling the pathogenesis of inflammatory bowel disease,
Nature, 2007, 448, 427-434.
116. A. Kaser, S. Zeissig and R. S. Blumberg, Inflammatory bowel disease, Annu. Rev. Immunol., 2010,
28, 573-621.
117. E. V. Loftus, Jr., Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and
environmental influences, Gastroenterology, 2004, 126, 1504-1517.
35
118. R. Al-Halabi, M. Bou Chedid, R. Abou Merhi, H. El-Hajj, H. Zahr, R. Schneider-Stock, A. Bazarbachi
and H. Gali-Muhtasib, Gallotannin inhibits NFkB signaling and growth of human colon cancer
xenografts, Cancer Biol. Ther., 2011, 12, 59-68.
119. A. C. Carvalho, M. M. Guedes, A. L. de Souza, M. T. Trevisan, A. F. Lima, F. A. Santos and V. S.
Rao, Gastroprotective effect of mangiferin, a xanthonoid from Mangifera indica, against gastric
injury induced by ethanol and indomethacin in rodents, Planta Med., 2007, 73, 1372-1376.
120. J.-J. Jeong, S.-E. Jang, S. R. Hyam, M. J. Han and D.-H. Kim, Mangiferin ameliorates colitis by
inhibiting IRAK1 phosphorylation in NF-κB and MAPK pathways, Eur. J. Pharmacol., 2014, 740,
652-661.
121. S. M. Lim, J. J. Jeong, H. S. Choi, H. B. Chang and D. H. Kim, Mangiferin corrects the imbalance of
Th17/Treg cells in mice with TNBS-induced colitis, Int. Immunopharmacol., 2016, 34, 220-228.
122. S. M. Lim, G. D. Kang, J. J. Jeong, H. S. Choi and D. H. Kim, Neomangiferin modulates the
Th17/Treg balance and ameliorates colitis in mice, Phytomedicine, 2016, 23, 131-140.
123. M. Mahmoud-Awny, A. S. Attia, M. F. Abd-Ellah and H. S. El-Abhar, Mangiferin Mitigates Gastric
Ulcer in Ischemia/ Reperfused Rats: Involvement of PPAR-gamma, NF-kappaB and Nrf2/HO-1
Signaling Pathways, PLoS One, 2015, 10, e0132497.
124. L. Marquez, B. Garcia-Bueno, J. L. Madrigal and J. C. Leza, Mangiferin decreases inflammation
and oxidative damage in rat brain after stress, Eur. J. Nutr., 2012, 51, 729-739.
125. T. C. Morais, B. R. Arruda, H. de Sousa Magalhaes, M. T. Trevisan, D. de Araujo Viana, V. S. Rao
and F. A. Santos, Mangiferin ameliorates the intestinal inflammatory response and the impaired
gastrointestinal motility in mouse model of postoperative ileus, Naunyn Schmiedebergs Arch.
Pharmacol., 2015, 388, 531-538.
126. C. E. O’Neil, T. A. Nicklas and V. L. Fulgoni, Mangoes are Associated with Better Nutrient Intake,
Diet Quality, and Levels of Some Cardiovascular Risk Factors: National Health and Nutrition
Examination Survey., J Nutr Food Sci, 2013, 3, 185.

Table 1: Nutritional Content of the Mango Fruit

Value/100g Mangos, edible fruit flesh

Water (g) 83.46

Energy (kcal) 60
Protein (g) 0.82

36
Total lipid (fat) (g) 0.38
Carbohydrate, by difference (g) 14.98
Fiber, total dietary (g) 1.6
Sugars, total (g) 13.66
Minerals
Calcium, Ca (mg) 11
Iron, Fe (mg) 0.16
Magnesium, Mg (mg) 10
Phosphorus, P (mg) 14
Potassium, K (mg) 168
Sodium, Na (mg) 1
Zinc, Zn (mg) 0.09
Vitamins
Vitamin C, total ascorbic acid (mg) 36.4
Thiamin (mg) 0.028
Riboflavin (mg) 0.038
Niacin (mg) 0.669
Pantothenic acid (mg) 0.119
Folate, DFE (µg) 43
Vitamin A, RAE (µg) 54
Vitamin A, IU 1082
Vitamin E (alpha-tocopherol) (mg) 0.90
Vitamin K (phylloquinone) (µg) 4.2
Lipids
Fatty acids, total saturated (g) 0.092
Fatty acids, total monounsaturated (g) 0.14
Fatty acids, total polyunsaturated (g) 0.071

37
 Fatty acids, total trans (g) 0
Cholesterol (g) 0
Carotenoids
Beta-carotene (µg) 640
Alpha-carotene (µg) 9
Beta cryptoxanthin (µg) 10
Lycopene (µg) 3
Lutein and zeaxanthin (ug) 23
Polyphenols
Cyanidin (mg) 0.10
Catechin (mg) 1.7
Kaempferol (mg) 0.1
Myricetin (mg) 0.1
Proanthocyanidin dimers (mg) 1.8
Proanthocyanidin trimers (mg) 1.4
Proanthocyanidin 4-6mers (mg) 7.2

Source: National Nutrient Database for Standard Reference Service Release 28 Agricultural
Research Services, United States Department of Agriculture, slightly revised May 2016. RAE-
retinol activity equivalent; DFE-dietary folate equivalent

38
Table 2: Mango Bioaccessibility and Bioavailability

STUDY DETAILS RESULTS

Ref First Bio- Methods, generally Treatment Analytical
# Author Accessibility Chemistry
Date Availability
Model
52 Epriliati I in vivo Effects of processing and in vitro digestion steps on Mango Fresh Dried and fresh fruits released lower levels
2009 Human carotenoid, sugar, and organic acid release from mango Mango Juice of nutriome components than juices. Pectin
mastication products were comprehensively studied. In vivo Mango Dried may play a role in determining the rate of
chewing experiments using 24 healthy adult volunteers nutriome release and absorption
in vitro was carried out prior to chewing simulation.
digestion and
absorption

53 Epriliati I in vitro Caco-2 cell monolayers as human intestinal absorption Mango Fresh Phytochemical constituents, including
2009 Cells models were used to investigate nutriome passages Mango Juice carotenoids suspected to NOT be absorbed
from fruit digest solutions. Passage of sugars, organic Mango Dried from small intestine based on this model
Caco-2 acids, major phytochemicals (disappearances of apical
carotenoids and phenolics).

54 Ornelas- in vivo Vitamin A depleted rats were fed with vitamin A and Mango flesh ↑ retinol accumulation was found in rats
Paz Jde Animal carotenoid deficient diet and one of 5 the test foods for Carrot feeding the β carotene + oil.
2010 2 weeks (Mango fruit cubes, carrot slices, synthetic β β carotene
Vitamin A carotene ± soybean oil. The rats were sacrificed to Rats fed with carrots accumulated 37% less
depleted rats measure liver retinol. 2 weeks retinol than those feeding mango without
oil.

39
55 Low DY in vivo To investigate effect of mastication on carotenoid Mango cubes Small particle size ↑ % release of
2015 Human bioaccessibility from mango fruit tissue. After In vivo carotenoids after digestion
Mastication human mastication of mango pulp (coarse and fine
chewer), collected chewed boluses were fractionated Large particle size
simulated by wet sieving followed by gastrointestinal digestion. ↑ content of total carotenoids
gastrointestinal
digestion Bioaccessible = Xanthophylls > β-carotene
irrespective of particle sizes

Chewing reduced release of β-carotene

(34%) and xanthophylls (by 18%).

56 Low DY in vivo To study the microbial biotransformation of Mango cubes Microbial metabolism-ring fission,
2016 Human polyphenols during in vitro colonic fermentation (48 h) dihydroxylation and decarboxylation
Mastication of masticated mango and banana.
Formation of catabolites
in vitro 4-hydroxyphenylacetic acid (4-8 h)
digestion and Catechin derivative and 3-(4-
colonic hydroxyphenyl)propanoic acid (up to 48 h)
fermentation

57 Blancas- in vitro Study to test the bioaccessibility of polyphenols Mango Pulp Paste Polyphenols association with fiber
Benitez FJ Assay associated with dietary fiber (DF) and the kinetics Mango Peel Soluble DF > Insoluble DF
2015 release of polyphenols in mango (Ataulfo) paste and
peel. ~40% bioaccessible

Gallic acid & hydroxybenzoic acid released

(paste, max ~180 min)

58 Liu X in vitro To investigate ways to increase the bioaccessibility of Mango Puree ↑

2016 Assay phenolics and carotenoids in mangoes. Oil-in-water Lipophilic bioactives (eg., carotenes)
excipient nanoemulsions using medium chain LCT>MCT>Buffer
simulated triglycerides (MCT) and long-chain triglycerides ↔
GIT (LCT) were prepared, mixed with pureed mango and Phenolics
passed through a simulated gastrointestinal tract (GIT).

40
 59 Ornelas- in vitro To study the impact of stage of ripening of mango and Mango pulp ↑ micellarization of β carotene with
Paz Jde Assay dietary fat on micellarization during digestion of β- Varied ripeness ripening stage and when fruit mixed with
2010 carotene (BC) and uptake by Caco 2 cells. Mango (SR, MR, FR) CBF.
Caco 2 cells (Ataulfo) pulp with varied ripeness (slightly ripe, SR; ±
moderately ripe, MR; fully ripe, FR) with or without CBF Uptake of β carotene was 17% by Caco 2
chicken baby food (CBF) cells.

60 Gouado I in vivo Two groups (n=7 each) of healthy weight young adults Mango Fresh (568 g) ↑
2007 Human (mid-20s y, BMI ~ 21.5 kg/m2) were fed fresh, dried or Mango Juice (565 g) carotenoids in plasma
juice of mango or papaya with bread and yogurt for Mango Dried (100 g)
Healthy breakfast. Blood collected at 0, 4, 8 h. Plasma Juice, Fresh > Dried for Bioavailability
carotenoids (lutein, alpha-carotene, beta-carotene,
lycopene, cryptoxanthin) and bioavailability measured. acute 8 h

61 Barnes RC in vivo One-arm human pilot trial, healthy volunteers (age = Mango Pulp 7 metabolites of GA identified (urine)
2016 Human 21-38 y, n = 11) consumed 400 g/day of mango-pulp ↑ 2 metabolites after 10 d feed
(Keitt cultivar) for 10 days. Urine (12 h) and plasma 400 g / day
Healthy analyzed for metabolites of gallotannins (GT), gallic 10 days metabolites not detected in plasma
acid, mangiferin.

Arrows: ↑(increase)

41
 Table 3: In vivo animal research on the anti- Obesity and anti-Diabetes effects of consuming Mango flesh.

STUDY DETAILS RESULTS

Ref First Disease Methods, generally Treatments Risk factors/ Oxidative & Other
# Author area and Duration Biomarkers Inflammation data of interest
Date Model Biomarkers
↓, ↔, ↑ ↓, ↔, ↑ ↓, ↔, ↑

64 Gomes Obesity The effect of Ubá mango juice with and without Mango Juice (MJ) HF+MJ vs HF HF+MJ vs HF HF+MJ vs HF
Natal DI peel extract (PE) on metabolic indices and ↓ ↑ ↓
2016 adipose tissue and inflammation modulation in Diets: BW, FM (visceral) PPAR-γ, LPL adipose
Rats HF diet-induced obese Wistar rats. Control diet Control ↓ hypertrophy
High Fat (AIN-93M). HF Glucose, TG, TC, ↓
(HF) diet- HF+MJ TC/HDL, ALT, FAS, TNF-α
induced HF+MJ+PE AST
Obesity ↔
8 week HF+MJ ≥ benefit Interleukin 10
MJ = 35 mL/d to HF+MJ+PE

65 Lucas EA Obesity The effects of freeze-dried mango pulp (Tommy Mango Pulp (M) HF+M vs HF Mango results
2011 Atkins) in comparison with the hypolipidaemic ↔ not different
drug, fenofibrate, and the hypoglycaemic drug, Diets: BW from
Mice rosiglitazone, in reducing adiposity and Control ↓ Rosiglitazone
High Fat alterations in glucose metabolism and lipid HF+0% M Fat Mass
(HF) diet- profile in mice fed a high fat (HF, 60% fat HF+1% M ↑
induced energy) diet. Control diet (AIN-93M). HF+10% M Lean Mass
Obesity HF+Fenofibrate ↓
(500 mg/kg diet) Insulin Resistance
HF+Rosiglitazone ↑
(50 mg/kg diet) Glucose Tolerance
(1% Mango)
8 week
42
 ↓
Lipids

66 Ojo B Obesity The effects of freeze-dried mango pulp in a high Mango Pulp (M) HF+10% M vs HF HF+10% M vs HF HF+10% M
2016 fat (HF, 60% fat energy) diet on body weight ↑ ↑ prevented HF-
(BW), body composition, lipids, glucose, cecal Diets: BW, FM, Insulin, Interleukin 10 induced ↓ in
Mice microbial population (16S rDNA sequencing), Control non-HDL-c (colon) Bifidobacteria,
High Fat short-chain fatty acid production, and gut HF + 0% M Akkermansia
(HF) diet- inflammatory markers (mRNA abundance) in HF + 1% M ↔
induced ileum and colonic lamina propria in C57BL/6 HF + 10% M Glucose, TG, TC, HF+10% M vs
Obesity mice. Control diet (AIN-93M). HDL, PAI-1 HF
12 week ↑
fecal acetic and
butyric acids

67 Perpetuo Diabetes The effects of the intake of flour obtained from Mango Pulp Flour 30 day study: 30 day study:
GF mango pulp (Tommy Atkins) in normal and (MPF) 5,10,15% MPF ↔
2003 diabetic (DM) rats. No effect in normal rats. ↓ FI, BW
Results shown for DM rats only. Diets: Glucose
Rats Control (0% MPF) 90 day study:
Diabetic 5% MPF 90 day study: ↑
alloxan- 10% MPF 5% MPF FI, BW on 5%*
induced 15% MPF ↓
glucose * likely due to
30 days (all diets) ↑ better control of
and liver glycogen diabetes
90 days (0%, 5%) ↑
Insulin
Arrows: ↓(decrease); ↔ (no effect); ↑(increase)
ALT: AST: BW: body weight; FAS: fatty acid synthase; FI: food intake; FM: fat mass; HDL: high density lipoprotein; LPL: lipoprotein lipase;
non-HDL-c: non high density lipoprotein cholesterol; PAI 1: plasminogen activator inhibitor 1; PPAR-γ: peroxisome proliferator-activated
receptor gamma; TC: total cholesterol; TG: triglycerides

43
 Table 4: Biological Effects of Consuming Mango Fruit: In vivo Human Research
STUDY DETAILS RESULTS
Ref First Author Disease Methods, generally Treatment Risk factors/ Other
# Date area and Duration Biomarkers data of interest
Model
↓, ↔, ↑ ↓, ↔, ↑
68 Contractor Z Diabetes Three-arm randomized controlled crossover design. Mango Mango Fruit (M) ↔
1999 and Sapota effects on glycemic responses compared to glucose (AUC)
T2DM banana in people with type 2 diabetes (T2DM, n=10). Diets:
Banana control Control (banana)* M vs Control
Outcomes: Glucose Mango*
Sapota*

*equi-25 g
carbohydrate

Acute 3 h

69 Edo AE Diabetes Multi-arm randomized controlled crossover design. Various Mango Fruit (M) M vs Control
2011 fruits, including mango, were studied in people with type 2 ↓
T2DM diabetes mellitus (T2DM, n=10). Glucose as control. Diets: Glucose (PGR)
Outcomes: Plasma glucose resposnes (PGR) was assessed Control (glucose)*
by peak plasma glucose concentration (PPPG), maximum Mango* M vs other fruits
increase in postprandial plasma glucose (MIPG), 2h PG, Other Fruits* ↓
incremental area under the glucose curve (IAUGC). MIPG, IAUGC
*equi-50 g
carbohydrate

acute 2 h

44
70 Elizondo- Diabetes Three-arm randomized controlled crossover design. Healthy Mango Puree (MP) MP vs Control ↑
Montemayor L Mexican adults (n=38, 19 male, 19 female) participated in a ↓ puree viscosity
2015 Healthy randomized cross-over clinical trial to test glycemic Diets: AUC Glucose, GI with HP
responses to fresh mango puree (Tommy Atkins) processed Control (glucose)
by hydrostatic pressure (HP) vs unprocessed (UnP) UnP-MP HP-MP vs UnP-MP
Outcomes: glycemic index (GI) and postprandial glycemic HP-MP ↓
responses. Glucose (AUC), GI
acute 2 h

71 Evans SF Obesity One-arm human trial. Twenty obese adults (11 males, 9 Mango Pulp (M) M vs baseline ↓
2014 females) ages 20-50 years old consumed freeze-dried mango ↔ hip circumference
Obese pulp (10 g/d) for 12 weeks. Diets: BW (males)
Outcomes: Anthropometrics, biochemical parameters, and freeze-dried M 10 ↔
body composition were assessed at baseline and after 12 g/d Body Composition
weeks mango supplementation. ↓
12 week glucose

72 Fatema K Diabetes Three-arm randomized controlled crossover design. Ranking Mango Fruit (M) M vs Control 72
2003 of mango and papaya (Bangladeshi type) on glycemic index ↑
T2DM (GI) and insulinemic index (II) in people with type 2 Diets: glucose
diabetes (T2DM, n=13) over 3 h. White bread (WB) control. Control (WB)* ↔
Outcomes: Insulin, glucose, C-peptide Serum C-peptide 250 g Mango* insulin, C-peptide
602 g Papaya*

*equi-25 g
carbohydrate

Acute 3 h

45
73 Guevarra MT Diabetes Multi-arm randomized controlled crossover design. Ranking Mango Fruit (M) M vs Control
2000 of fruits, including mango on glycemic responses in people ↓
T2DM with type 2 diabetes (T2DM, n=10). Wheat bread (WB) Diets: glucose (AUC)
control. Control (WB)*
Outcomes: Glucose and Glycemic index (GI) Mango* GI ~ 59
Other tropical fruits*

*equi-25 g
carbohydrate

Acute 3 h

74 Roongpisuthipong Diabetes Multi-arm randomized crossover design. Mango compared Mango Fruit (M) M vs P, D, R
C to 4 other tropical fruits (banana, B; pineapple, P; durian, D; ↓
1991 T2DM rambutan, R) on glycemic responses in people with type 2 Diets: glucose (AUC)
diabetes (T2DM, female, n=10). No control group. Mango*
Outcomes: Glucose and Insulin Other tropical fruits* M vs B
↔
*equi-25 g glucose (AUC)
carbohydrate

Acute 3 h M vs D
↓
insulin (AUC)

M vs B, P, R
↔
Insulin (AUC)

46
92 Gerstgrasser A CVD Two-arm, double-blinded, randomized cross over design. No Mango Fruit powder ↑ In vitro
2016 control group. Healthy adults (n=10) consumed Careless™ Careless™ cutaneous blood flow ↑
Healthy (pure unripe mango fruit powder, Kili-Mooku cultivar). vs eNOS
Outcomes: Microcirculation and endothelial function were 100, 300 mg Baseline dose-dependently
assessed by the Oxygen-to-see system and EndoPAT™, no control group (w/100 mg dose) (Careless™ tested
respectively at 0-3000 µg/mL)
Acute 6 h ↔
hyperemia

Arrows: ↓(decrease); ↔ (no effect); ↑(increase)

AUC: area under curve; BW: body weight; eNOS: endothelial nitric oxide synthase

47
 Table 5: Emerging Areas of Mango Health Benefits: In vivo animal research in brain, skin and intestinal health.
STUDY DETAILS RESULTS
Ref First Author Disease area Methods, generally Treatments Risk factors/ Oxidative &
# Date and Duration Biomarkers Inflammation Biomarkers
Model ↓, ↔, ↑
↓, ↔, ↑

75 Kim H Intestinal Mango (Keitt) and pomegranate (POM) Mango Pulp ↔ ↓

2016 beverages were tested in colitis model on beverage (MB) ulceration mucosal
intestinal inflammation and pro-inflammatory ↔ mRNA TNF-α, IL-1β, IL-6
cytokines in mucosa and serum. Diets: saquamous ↓
Rat Outcomes: intestinal ulceration, pro- and anti- Control metaplasia serum: IL-1β, IL-6
DSS-induced inflammatory cytokines MB ↓ ↑
Colitis Pomogranate (POM) colonic cell IL-10
proliferation ↓
10 weeks PI3K/AKT/ mTOR
↓
miR-126, Let-7a ↔
miR-21, miR-145, and miR-
155

76 Kim H Intestinal Mango (Keitt) beverage was tested in colitis Mango Pulp ↔ ↓
2016 model assessing intestinal inflammation and beverage (MB) ulceration mucosal
pro-inflammatory cytokines in mucosa. mRNA TNF-α, IL-1β,
Outcomes: intestinal ulceration, inflammatory Diets: iNOS, COX-2
Rat cytokines, NF-κB, iNOS, COX-2 and IGF-1R- Control (0 g MB) ↓
DSS-induced AKT/mTOR MB ~90 mg GAE/kg/d protein levels of : TNF-α,
Colitis IL-1β, IL-6, iNOS
6-8 weeks ↓
PI3K/AKT/ mTOR
↓
miR-126, Let-7a ↔
miR-21, miR-145, miR-155

48
108 Kumar S Brain Ethanol extract of ripe Mango from local store Mango Fruit Extract ↓
2009 was fed to mice for 7 days. (MFE) aging and
memory Cognitive performances were examined using scopolamine
step down passive avoidance task and elevated Diets: induced memory
Mice plus maze task. Control (0 mg/kg MFE) deficits in both
250 MFE mg/kg tasks.
500 MFE mg/kg Similar to Vit C
250 VitC mg/kg

7 day

109 Wattanathorn Brain Effects of mango fruit extract on memory Mango Fruit Extract ↑ All dose
J impairment, cholinergic dysfunction, and (MFE) memory ↓
2014 memory oxidative stress damage in animal model of Ox Stress
mild cognitive impairment. Diets: ↑ hippo campus
Rats Outcomes: spatial memory, cholinergic Control cholinergic neuron
MCI neurons density, MDA level, and the activities 12.5 MFE mg/kg density ↓
of SOD, CAT, and GSH-Px enzymes in 50 MFE mg/kg (50, 200 mg doses) MDA
hippocampus. 200 VitC mg/kg
↑
2 weeks pre- and SOD
1 week post- MCI GSH-Px
induction

49
111 Song JH Skin Evaluation of water extract from dried mango Mango Extract (ME) ↓
2013 against UVB-induced skin aging in hairless Wrinkle length and
Mice mice. Outcomes: wrinkle formation, epidermal Diets: depth
UVB-induced thickness, collagen fiber damage. Control Control
skin aging condition includes no UVB and no ME. UVB (0 mg/kg ME) ↓
UVB (100 mg/kg ME) collagen fiber
damage
12 weeks
↓
skin thickness

Arrows: ↓(decrease); ↔ (no effect); ↑(increase)

CAT: catalase; COX-2: cyclooxygenase-2; DSS: dextran sodium sulfate; GAE: gallic acid equivalent; GSH-Px; glutathione peroxidase; iNOS:
inducible nitric oxide synthase; IL-1β: interleukin-1 beta; IL-6: interleukin-6; IL-10: interleukin-10; MCI: mild cognitive impairment; MDA:
malondialdehyde; mTOR: mammalian target of rapamycin; NF-κB: nuclear factor kappa-B; Ox: oxidative; SOD: superoxide dismutase; TNF-α:
tumor necrosis factor-alpha; UVB: ultraviolet B; Vit C: vitamin C

50
Figure Legends
Figure 1: Major phytochemicals in Mango pulp.
Figure 2: Potential health benefits of Mango consumption.

51
 Phenolic acids

OH

OH O
OH
O
OH
OH O
OH CH3

Gallic acid Ferulic acid

OH
O OH
O OH
O

HO O
OH
OH OH
OH OH

Protocatechuic acid Chlorogenic acid

Carotenoids

H3C
CH3 CH3 CH3 H3C

CH3 CH3 CH3 CH3

CH3

Beta carotene

52
Xanthones/Xanthonoids

HO
OH OH

OH O

HO RO O OH HO O OH
HO O
HO
OH OH
OH
O OH O

Mangiferin R=H
Homomangiferin R=Methyl group Isomangiferin

Flavonols

R2 OH

OH OH

R1 O HO O
OH

OH OH
OH O OH O

Kaempferol R1=OH, R2=H Myricetin

Quercetin R1=OH, R2=OH
Isorhamnetin R1=OH, R2=OMe

Flavan-3-als

53
 OH

HO O
OH

OH
OH

Catechin

Gallotannins

HO OH

OH

O
O
O
HO O
O O
HO OH
O O O O
OH
OH OH
O
OH
OH
HO OH
OH
OH

Pentagalloylglucose
Figure 1

54
Figure 2

55